Study ID,Study,Experiment Name,Experiment Notes,Strain Ont ID,Strain,Sex,Age,# of Animals,Sample Notes,Clinical Measurement Ont ID,Phenotype,Formula,Clinical Measurement Notes,Average Type,Value,Units,SEM,SD,Method Ont ID,Method,Method Site,Method Duration,Method Notes,Post Insult Type,Post Insult Time Value,Post Insult Time Unit,Conditions,Record ID,Condition 1a,Condition 1b,Condition 1c,Condition 2a,Condition 2b,Condition 2c,Condition 3a,Condition 3b,Condition 3c 114,"Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8",central nervous system integrity trait,,RS:0002074,N:HS,both,177 days to 132 days,217,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,41,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,myelin oligodendrocyte glycoprotein (50-120 ug) and Freund's complete adjuvant (100 ul) ,66040,myelin oligodendrocyte glycoprotein (50-120 ug) ,Freund's complete adjuvant (100 ul) ,,,,,,, 653,"Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106.",mammary gland integrity trait,,RS:0003347,WF.WKY-(D5Uwm67-D5Uwm98)/Uwm,female,160 days to 155 days,35,,CMO:0000343,mammary tumor number,,,,3.2,,0.4,2.3664,MMO:0000163,in vivo visual assessment,,0.0,,,,,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",70296,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",,,,,,,, 653,"Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106.",mammary gland integrity trait,,RS:0003348,WF.WKY-(D5Uwm76-D5Uwm61)/Uwm,female,160 days to 155 days,40,,CMO:0000343,mammary tumor number,,,,4.2,,0.4,2.5298,MMO:0000163,in vivo visual assessment,,0.0,,,,,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",70297,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",,,,,,,, 653,"Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106.",mammary gland integrity trait,,RS:0003349,WF.WKY-(D5Uwm76-D5Uwm98)/Uwm,female,160 days to 155 days,26,,CMO:0000343,mammary tumor number,,,,3.8,,0.4,2.0396,MMO:0000163,in vivo visual assessment,,0.0,,,,,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",70298,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",,,,,,,, 653,"Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106.",mammary gland integrity trait,,RS:0003350,WF.WKY-(D5Uwm67-D5Uwm78)/Uwm,female,160 days to 155 days,32,,CMO:0000343,mammary tumor number,,,,8.6,,0.8,4.5255,MMO:0000163,in vivo visual assessment,,0.0,,,,,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",70299,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",,,,,,,, 653,"Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106.",mammary gland integrity trait,,RS:0003351,WF.WKY-(D5Uwm76-D5Got18)/Uwm,female,160 days to 155 days,27,,CMO:0000343,mammary tumor number,,,,3.5,,0.4,2.0785,MMO:0000163,in vivo visual assessment,,0.0,,,,,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",70300,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",,,,,,,, 653,"Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106.",mammary gland integrity trait,,RS:0003352,WF.WKY-(D5Uwm78-D5Uwm98)/Uwm,female,160 days to 155 days,32,,CMO:0000343,mammary tumor number,,,,2.8,,0.3,1.6971,MMO:0000163,in vivo visual assessment,,0.0,,,,,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",70301,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",,,,,,,, 653,"Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106.",mammary gland integrity trait,,RS:0003353,WF.WKY-(D5Uwm95-D5Uwm98)/Uwm,female,160 days to 155 days,36,,CMO:0000343,mammary tumor number,,,,7.4,,0.6,3.6,MMO:0000163,in vivo visual assessment,,0.0,,,,,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",70302,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",,,,,,,, 653,"Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106.",mammary gland integrity trait,,RS:0003354,WF.WKY-(D5Uwm67-D5Uwm81)/Uwm,female,160 days to 155 days,26,,CMO:0000343,mammary tumor number,,,,8.3,,0.7,3.5693,MMO:0000163,in vivo visual assessment,,0.0,,,,,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",70303,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",,,,,,,, 653,"Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106.",mammary gland integrity trait,,RS:0003355,WF.WKY-(D5Uwm76-D5Uwm92)/Uwm,female,160 days to 155 days,58,,CMO:0000343,mammary tumor number,,,,4.8,,0.4,3.0463,MMO:0000163,in vivo visual assessment,,0.0,,,,,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",70304,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",,,,,,,, 653,"Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106.",mammary gland integrity trait,,RS:0003356,WF.WKY-(D5Uwm78-D5Uwm84)/Uwm,female,160 days to 155 days,29,,CMO:0000343,mammary tumor number,,,,8.8,,0.7,3.7696,MMO:0000163,in vivo visual assessment,,0.0,,,,,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",70305,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",,,,,,,, 653,"Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106.",mammary gland integrity trait,,RS:0003357,WF.WKY-(D5Uwm78-D5Uwm93)/Uwm,female,160 days to 155 days,27,,CMO:0000343,mammary tumor number,,,,5,,0.5,2.5981,MMO:0000163,in vivo visual assessment,,0.0,,,,,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",70306,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",,,,,,,, 653,"Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106.",mammary gland integrity trait,,RS:0003356,WF.WKY-(D5Uwm78-D5Uwm84)/Uwm,female,160 days to 155 days,41,,CMO:0000343,mammary tumor number,,,,8.1,,0.6,3.8419,MMO:0000163,in vivo visual assessment,,0.0,,,,,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",70307,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",,,,,,,, 653,"Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106.",mammary gland integrity trait,,RS:0003358,WF.WKY-(D5Uwm88-D5Uwm92)/Uwm,female,160 days to 155 days,58,,CMO:0000343,mammary tumor number,,,,6.9,,0.6,4.5695,MMO:0000163,in vivo visual assessment,,0.0,,,,,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",70308,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",,,,,,,, 653,"Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106.",mammary gland integrity trait,,RS:0003359,WF.WKY-(D5Uwm87-D5Uwm92)/Uwm,female,160 days to 155 days,56,,CMO:0000343,mammary tumor number,,,,6.3,,0.4,2.9933,MMO:0000163,in vivo visual assessment,,0.0,,,,,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",70309,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",,,,,,,, 653,"Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106.",mammary gland integrity trait,,RS:0003360,WF.WKY-(D5Uwm85-D5Uwm92)/Uwm,female,160 days to 155 days,51,,CMO:0000343,mammary tumor number,,,,3.9,,0.3,2.1424,MMO:0000163,in vivo visual assessment,,0.0,,,,,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",70310,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",,,,,,,, 653,"Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106.",mammary gland integrity trait,,RS:0003361,WF.WKY-(D5Uwm82-D5Uwm92)/Uwm,female,160 days to 155 days,18,,CMO:0000343,mammary tumor number,,,,2.6,,0.6,2.5456,MMO:0000163,in vivo visual assessment,,0.0,,,,,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",70311,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",,,,,,,, 653,"Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106.",mammary gland integrity trait,,RS:0003362,WF.WKY-(D5Uwm82-D5Uwm91)/Uwm,female,160 days to 155 days,58,,CMO:0000343,mammary tumor number,,,,3.4,,0.3,2.2847,MMO:0000163,in vivo visual assessment,,0.0,,,,,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",70312,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",,,,,,,, 653,"Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106.",mammary gland integrity trait,,RS:0003363,WF.WKY-(D5Uwm77-D5Uwm91)/Uwm,female,160 days to 155 days,12,,CMO:0000343,mammary tumor number,,,,3.8,,0.8,2.7713,MMO:0000163,in vivo visual assessment,,0.0,,,,,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",70313,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",,,,,,,, 653,"Veillet AL, et al., Cancer Prev Res (Phila). 2011 Jan;4(1):97-106.",mammary gland integrity trait,,RS:0000984,WF/NHsd,female,160 days to 155 days,46,,CMO:0000343,mammary tumor number,,,,7.9,,0.5,3.3912,MMO:0000163,in vivo visual assessment,,0.0,,,,,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",70314,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",,,,,,,, 654,"Sanders J, et al., PLoS One. 2011;6(5):e19891. Epub 2011 May 18.",mammary gland integrity trait,,RS:0002605,WF.WKY-(D7Rat171-D7Rat128)/2Uwm,female,160 days to 155 days,32,,CMO:0000343,mammary tumor number,,,,3.9,,0.4596,2.6,MMO:0000163,in vivo visual assessment,,0,,DMBA oral gavage,105,days,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",66061,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",,,,,,,, 654,"Sanders J, et al., PLoS One. 2011;6(5):e19891. Epub 2011 May 18.",mammary gland integrity trait,,RS:0002604,WF.WKY-(D7Rat171-D7Rat128)/1Uwm,female,160 days to 155 days,17,,CMO:0000343,mammary tumor number,,,,3.5,,0.6063,2.5,MMO:0000163,in vivo visual assessment,,0,,DMBA oral gavage,105,days,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",66060,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",,,,,,,, 654,"Sanders J, et al., PLoS One. 2011;6(5):e19891. Epub 2011 May 18.",mammary gland integrity trait,,RS:0002606,WF.WKY-(D7Rat51-D7Rat128)/Uwm,female,160 days to 155 days,23,,CMO:0000343,mammary tumor number,,,,8,,0.8549,4.1,MMO:0000163,in vivo visual assessment,,0,,DMBA oral gavage,105,days,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",66062,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",,,,,,,, 654,"Sanders J, et al., PLoS One. 2011;6(5):e19891. Epub 2011 May 18.",mammary gland integrity trait,,RS:0002607,WF.WKY-(D7Uwm25-D7Rat128)/Uwm,female,160 days to 155 days,43,,CMO:0000343,mammary tumor number,,,,7.2,,0.4575,3.0,MMO:0000163,in vivo visual assessment,,0,,DMBA oral gavage,105,days,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",66063,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",,,,,,,, 654,"Sanders J, et al., PLoS One. 2011;6(5):e19891. Epub 2011 May 18.",mammary gland integrity trait,,RS:0002608,WF.WKY-(D7Rat171-D7Rat45)/Uwm,female,160 days to 155 days,28,,CMO:0000343,mammary tumor number,,,,3.4,,0.3969,2.1,MMO:0000163,in vivo visual assessment,,0,,DMBA oral gavage,105,days,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",66064,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",,,,,,,, 654,"Sanders J, et al., PLoS One. 2011;6(5):e19891. Epub 2011 May 18.",mammary gland integrity trait,,RS:0002609,WF.COP-(D7Rat39-D7Uwm12)/1Uwm,female,160 days to 155 days,16,,CMO:0000343,mammary tumor number,,,,2.4,,0.4,1.6,MMO:0000163,in vivo visual assessment,,0,,DMBA oral gavage,105,days,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",66065,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",,,,,,,, 654,"Sanders J, et al., PLoS One. 2011;6(5):e19891. Epub 2011 May 18.",mammary gland integrity trait,,RS:0002610,WF.COP-(D7Rat39-D7Uwm12)/2Uwm,female,160 days to 155 days,16,,CMO:0000343,mammary tumor number,,,,2,,0.375,1.5,MMO:0000163,in vivo visual assessment,,0,,DMBA oral gavage,105,days,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",66066,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",,,,,,,, 654,"Sanders J, et al., PLoS One. 2011;6(5):e19891. Epub 2011 May 18.",mammary gland integrity trait,,RS:0000982,WF,female,160 days to 155 days,19,,CMO:0000343,mammary tumor number,,,,7.3,,0.8259,3.6,MMO:0000163,in vivo visual assessment,,0,,DMBA oral gavage,105,days,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",66067,"7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)",,,,,,,, 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",central nervous system integrity trait,,RS:0000197,DA.ACI-(D10Rat12-D10Rat144),not specified,105 days to 63 days,7,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,,,14.4,d,2.8,7.4081,MMO:0000163,in vivo visual assessment,whole animal,0.0,range 31 to 40 days,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,68221,myelin oligodendrocyte glycoprotein (200 ul) ,,,,,,,, 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",central nervous system integrity trait,,RS:0000197,DA.ACI-(D10Rat12-D10Rat144),not specified,105 days to 63 days,13,,CMO:0001402,percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time,,"relap, %",,38.5,%,,,MMO:0000163,in vivo visual assessment,whole animal,0.0,range 31 to 40 days,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,68222,myelin oligodendrocyte glycoprotein (200 ul) ,,,,,,,, 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,not specified,105 days to 63 days,14,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,,,18.5,d,1.6,5.9867,MMO:0000163,in vivo visual assessment,whole animal,0.0,range 31 to 40 days,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,68224,myelin oligodendrocyte glycoprotein (200 ul) ,,,,,,,, 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,not specified,105 days to 63 days,16,,CMO:0001402,percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time,,,,81.3,%,,,MMO:0000163,in vivo visual assessment,whole animal,0.0,range 31 to 40 days,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,68225,myelin oligodendrocyte glycoprotein (200 ul) ,,,,,,,, 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",central nervous system integrity trait,,RS:0000198,DA.ACI-(D10Rat15-D10Rat29),not specified,105 days to 63 days,10,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,,,8.6,d,1.5,4.7434,MMO:0000163,in vivo visual assessment,whole animal,0.0,range 31 to 40 days,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,68227,myelin oligodendrocyte glycoprotein (200 ul) ,,,,,,,, 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",central nervous system integrity trait,,RS:0000198,DA.ACI-(D10Rat15-D10Rat29),not specified,105 days to 63 days,13,,CMO:0001402,percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time,,"relap, %",,30.8,%,,,MMO:0000163,in vivo visual assessment,whole animal,0.0,range 31 to 40 days,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,68228,myelin oligodendrocyte glycoprotein (200 ul) ,,,,,,,, 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",central nervous system integrity trait,,RS:0000201,DA.ACI-(D10Rat219-D10Rat29),not specified,105 days to 63 days,13,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,,,7.4,d,1.2,4.3267,MMO:0000163,in vivo visual assessment,whole animal,0.0,range 31 to 40 days,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,68230,myelin oligodendrocyte glycoprotein (200 ul) ,,,,,,,, 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",central nervous system integrity trait,,RS:0000201,DA.ACI-(D10Rat219-D10Rat29),not specified,105 days to 63 days,16,,CMO:0001402,percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time,,expressed as a fraction of total number of animals,,25,%,,,MMO:0000163,in vivo visual assessment,whole animal,0.0,range 31 to 40 days,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,68231,myelin oligodendrocyte glycoprotein (200 ul) ,,,,,,,, 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",central nervous system integrity trait,,RS:0000201,DA.ACI-(D10Rat219-D10Rat29),not specified,105 days to 63 days,10,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,60,%,,,MMO:0000163,in vivo visual assessment,whole animal,0.0,range 31 to 40 days,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,67873,myelin oligodendrocyte glycoprotein (200 ul) ,,,,,,,, 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",central nervous system integrity trait,,RS:0000201,DA.ACI-(D10Rat219-D10Rat29),not specified,105 days to 63 days,16,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,81.2,%,,,MMO:0000163,in vivo visual assessment,whole animal,0.0,range 31 to 40 days,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,67874,myelin oligodendrocyte glycoprotein (200 ul) ,,,,,,,, 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",central nervous system integrity trait,,RS:0000196,DA.ACI-(D10Rat10-D10Rat142),not specified,105 days to 63 days,7,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,85.7,%,,,MMO:0000163,in vivo visual assessment,whole animal,0.0,range 31 to 40 days,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,67875,myelin oligodendrocyte glycoprotein (200 ul) ,,,,,,,, 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",central nervous system integrity trait,,RS:0000197,DA.ACI-(D10Rat12-D10Rat144),not specified,105 days to 63 days,13,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,53.8,%,,,MMO:0000163,in vivo visual assessment,whole animal,0.0,range 31 to 40 days,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,67876,myelin oligodendrocyte glycoprotein (200 ul) ,,,,,,,, 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",central nervous system integrity trait,,RS:0000199,DA.ACI-(D10Rat2-D10Rat29)/Kini,not specified,105 days to 63 days,1,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,,,3,d,0.0,0.0,MMO:0000163,in vivo visual assessment,whole animal,0.0,range 31 to 40 days,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,68730,myelin oligodendrocyte glycoprotein (200 ul) ,,,,,,,, 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",central nervous system integrity trait,,RS:0000199,DA.ACI-(D10Rat2-D10Rat29)/Kini,not specified,105 days to 63 days,6,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,,,13.3,d,2.6,6.3687,MMO:0000163,in vivo visual assessment,whole animal,0.0,range 31 to 40 days,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,68731,myelin oligodendrocyte glycoprotein (200 ul) ,,,,,,,, 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",central nervous system integrity trait,,RS:0000199,DA.ACI-(D10Rat2-D10Rat29)/Kini,not specified,105 days to 63 days,8,,CMO:0001402,percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time,,,,37.5,%,,,MMO:0000163,in vivo visual assessment,whole animal,0.0,range 31 to 40 days,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,68732,myelin oligodendrocyte glycoprotein (200 ul) ,,,,,,,, 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",central nervous system integrity trait,,RS:0000199,DA.ACI-(D10Rat2-D10Rat29)/Kini,not specified,105 days to 63 days,7,,CMO:0001402,percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,whole animal,0.0,range 31 to 40 days,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,68733,myelin oligodendrocyte glycoprotein (200 ul) ,,,,,,,, 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",central nervous system integrity trait,,RS:0000199,DA.ACI-(D10Rat2-D10Rat29)/Kini,not specified,105 days to 63 days,7,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,14.3,%,,,MMO:0000163,in vivo visual assessment,whole animal,0.0,range 31 to 40 days,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,68734,myelin oligodendrocyte glycoprotein (200 ul) ,,,,,,,, 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",central nervous system integrity trait,,RS:0000199,DA.ACI-(D10Rat2-D10Rat29)/Kini,not specified,105 days to 63 days,8,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,75,%,,,MMO:0000163,in vivo visual assessment,whole animal,0.0,range 31 to 40 days,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,68735,myelin oligodendrocyte glycoprotein (200 ul) ,,,,,,,, 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",central nervous system integrity trait,,RS:0000198,DA.ACI-(D10Rat15-D10Rat29),not specified,105 days to 63 days,12,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,,,3.5,d,1.7,5.889,MMO:0000163,in vivo visual assessment,whole animal,0.0,range 31 to 40 days,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,68194,myelin oligodendrocyte glycoprotein (200 ul) ,,,,,,,, 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",central nervous system integrity trait,,RS:0000198,DA.ACI-(D10Rat15-D10Rat29),not specified,105 days to 63 days,12,,CMO:0001402,percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time,,,,8.3,%,,,MMO:0000163,in vivo visual assessment,whole animal,0.0,range 31 to 40 days,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,68195,myelin oligodendrocyte glycoprotein (200 ul) ,,,,,,,, 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,not specified,105 days to 63 days,8,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,,,13,d,1.8,5.0912,MMO:0000163,in vivo visual assessment,whole animal,0.0,range 31 to 40 days,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,68197,myelin oligodendrocyte glycoprotein (200 ul) ,,,,,,,, 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,not specified,105 days to 63 days,10,,CMO:0001402,percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time,,,,70,%,,,MMO:0000163,in vivo visual assessment,whole animal,0.0,range 31 to 40 days,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,68198,myelin oligodendrocyte glycoprotein (200 ul) ,,,,,,,, 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,not specified,105 days to 63 days,8,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,,,16.4,d,2.6,7.3539,MMO:0000163,in vivo visual assessment,whole animal,0.0,range 31 to 40 days,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,68200,myelin oligodendrocyte glycoprotein (200 ul) ,,,,,,,, 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,not specified,105 days to 63 days,8,,CMO:0001402,percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time,,,,87.5,%,,,MMO:0000163,in vivo visual assessment,whole animal,0.0,range 31 to 40 days,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,68201,myelin oligodendrocyte glycoprotein (200 ul) ,,,,,,,, 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",central nervous system integrity trait,,RS:0000198,DA.ACI-(D10Rat15-D10Rat29),not specified,105 days to 63 days,5,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,,,13.4,d,2.0,4.4721,MMO:0000163,in vivo visual assessment,whole animal,0.0,range 31 to 40 days,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,68203,myelin oligodendrocyte glycoprotein (200 ul) ,,,,,,,, 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",central nervous system integrity trait,,RS:0000198,DA.ACI-(D10Rat15-D10Rat29),not specified,105 days to 63 days,8,,CMO:0001402,percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time,,,,37.5,%,,,MMO:0000163,in vivo visual assessment,whole animal,0.0,range 31 to 40 days,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,68204,myelin oligodendrocyte glycoprotein (200 ul) ,,,,,,,, 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",central nervous system integrity trait,,RS:0000200,DA.ACI-(D10Rat2-D10Rat6),not specified,105 days to 63 days,8,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,,,18.9,d,2.2,6.2225,MMO:0000163,in vivo visual assessment,whole animal,0.0,range 31 to 40 days,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,68206,myelin oligodendrocyte glycoprotein (200 ul) ,,,,,,,, 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",central nervous system integrity trait,,RS:0000200,DA.ACI-(D10Rat2-D10Rat6),not specified,105 days to 63 days,8,,CMO:0001402,percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time,,,,87.5,%,,,MMO:0000163,in vivo visual assessment,whole animal,0.0,range 31 to 40 days,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,68207,myelin oligodendrocyte glycoprotein (200 ul) ,,,,,,,, 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,not specified,105 days to 63 days,14,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,,,13.4,d,2.2,8.2316,MMO:0000163,in vivo visual assessment,whole animal,0.0,range 31 to 40 days,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,68209,myelin oligodendrocyte glycoprotein (200 ul) ,,,,,,,, 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,not specified,105 days to 63 days,16,,CMO:0001402,percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time,,,,56.3,%,,,MMO:0000163,in vivo visual assessment,whole animal,0.0,range 31 to 40 days,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,68210,myelin oligodendrocyte glycoprotein (200 ul) ,,,,,,,, 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",central nervous system integrity trait,,RS:0000198,DA.ACI-(D10Rat15-D10Rat29),not specified,105 days to 63 days,4,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,,,8.7,d,2.8,5.6,MMO:0000163,in vivo visual assessment,whole animal,0.0,range 31 to 40 days,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,68212,myelin oligodendrocyte glycoprotein (200 ul) ,,,,,,,, 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",central nervous system integrity trait,,RS:0000198,DA.ACI-(D10Rat15-D10Rat29),not specified,105 days to 63 days,10,,CMO:0001402,percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time,,,,30,%,,,MMO:0000163,in vivo visual assessment,whole animal,0.0,range 31 to 40 days,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,68213,myelin oligodendrocyte glycoprotein (200 ul) ,,,,,,,, 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",central nervous system integrity trait,,RS:0000201,DA.ACI-(D10Rat219-D10Rat29),not specified,105 days to 63 days,6,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,,,11.5,d,2.6,6.3687,MMO:0000163,in vivo visual assessment,whole animal,0.0,range 31 to 40 days,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,68215,myelin oligodendrocyte glycoprotein (200 ul) ,,,,,,,, 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",central nervous system integrity trait,,RS:0000201,DA.ACI-(D10Rat219-D10Rat29),not specified,105 days to 63 days,10,,CMO:0001402,percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time,,,,40,%,,,MMO:0000163,in vivo visual assessment,whole animal,0.0,range 31 to 40 days,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,68216,myelin oligodendrocyte glycoprotein (200 ul) ,,,,,,,, 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",central nervous system integrity trait,,RS:0000196,DA.ACI-(D10Rat10-D10Rat142),not specified,105 days to 63 days,6,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,,,13.5,d,3.1,7.5934,MMO:0000163,in vivo visual assessment,whole animal,0.0,range 31 to 40 days,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,68218,myelin oligodendrocyte glycoprotein (200 ul) ,,,,,,,, 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",central nervous system integrity trait,,RS:0000196,DA.ACI-(D10Rat10-D10Rat142),not specified,105 days to 63 days,7,,CMO:0001402,percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time,,,,71.4,%,,,MMO:0000163,in vivo visual assessment,whole animal,0.0,range 31 to 40 days,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,68219,myelin oligodendrocyte glycoprotein (200 ul) ,,,,,,,, 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",central nervous system integrity trait,,RS:0000198,DA.ACI-(D10Rat15-D10Rat29),not specified,105 days to 63 days,12,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,33.3,%,,,MMO:0000163,in vivo visual assessment,whole animal,0.0,range 31 to 40 days,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,67848,myelin oligodendrocyte glycoprotein (200 ul) ,,,,,,,, 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,not specified,105 days to 63 days,10,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,80,%,,,MMO:0000163,in vivo visual assessment,whole animal,0.0,range 31 to 40 days,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,67849,myelin oligodendrocyte glycoprotein (200 ul) ,,,,,,,, 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,not specified,105 days to 63 days,8,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,whole animal,0.0,range 31 to 40 days,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,67850,myelin oligodendrocyte glycoprotein (200 ul) ,,,,,,,, 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,not specified,105 days to 63 days,16,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,87.5,%,,,MMO:0000163,in vivo visual assessment,whole animal,0.0,range 31 to 40 days,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,67852,myelin oligodendrocyte glycoprotein (200 ul) ,,,,,,,, 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,not specified,105 days to 63 days,16,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,87.5,%,,,MMO:0000163,in vivo visual assessment,whole animal,0.0,range 31 to 40 days,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,67853,myelin oligodendrocyte glycoprotein (200 ul) ,,,,,,,, 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",central nervous system integrity trait,,RS:0000198,DA.ACI-(D10Rat15-D10Rat29),not specified,105 days to 63 days,8,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,62.5,%,,,MMO:0000163,in vivo visual assessment,whole animal,0.0,range 31 to 40 days,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,67855,myelin oligodendrocyte glycoprotein (200 ul) ,,,,,,,, 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",central nervous system integrity trait,,RS:0000198,DA.ACI-(D10Rat15-D10Rat29),not specified,105 days to 63 days,10,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,40,%,,,MMO:0000163,in vivo visual assessment,whole animal,0.0,range 31 to 40 days,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,67856,myelin oligodendrocyte glycoprotein (200 ul) ,,,,,,,, 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",central nervous system integrity trait,,RS:0000198,DA.ACI-(D10Rat15-D10Rat29),not specified,105 days to 63 days,13,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,76.9,%,,,MMO:0000163,in vivo visual assessment,whole animal,0.0,range 31 to 40 days,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,67859,myelin oligodendrocyte glycoprotein (200 ul) ,,,,,,,, 829,"Jagodic M, et al., J Immunol 2004 Jul 15;173(2):1366-73.",central nervous system integrity trait,,RS:0000200,DA.ACI-(D10Rat2-D10Rat6),not specified,105 days to 63 days,8,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,whole animal,0.0,range 31 to 40 days,injection,40,days,myelin oligodendrocyte glycoprotein (200 ul) ,67860,myelin oligodendrocyte glycoprotein (200 ul) ,,,,,,,, 837,"Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,male,112 days to 91 days,22,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,82,%,,,MMO:0000163,in vivo visual assessment,,0.0,visual observation,,,,myelin oligodendrocyte glycoprotein (30 ug) and Freund's incomplete adjuvant (100 ul) ,69487,myelin oligodendrocyte glycoprotein (30 ug) ,Freund's incomplete adjuvant (100 ul) ,,,,,,, 837,"Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716.",central nervous system integrity trait,,RS:0002506,DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini,male,112 days to 91 days,21,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,76,%,,,MMO:0000163,in vivo visual assessment,,0.0,visual observation,,,,myelin oligodendrocyte glycoprotein (30 ug) and Freund's incomplete adjuvant (100 ul) ,69488,myelin oligodendrocyte glycoprotein (30 ug) ,Freund's incomplete adjuvant (100 ul) ,,,,,,, 837,"Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,male,112 days to 65 days,22,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,,,15.8,d,1.8975,8.9,MMO:0000163,in vivo visual assessment,,0.0,,,,,myelin oligodendrocyte glycoprotein (30 ug) and Freund's incomplete adjuvant (100 ul) ,69489,myelin oligodendrocyte glycoprotein (30 ug) ,Freund's incomplete adjuvant (100 ul) ,,,,,,, 837,"Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716.",central nervous system integrity trait,,RS:0002506,DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini,male,112 days to 65 days,21,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,,,11.7,d,2.2258,10.2,MMO:0000163,in vivo visual assessment,,0.0,,,,,myelin oligodendrocyte glycoprotein (30 ug) and Freund's incomplete adjuvant (100 ul) ,69490,myelin oligodendrocyte glycoprotein (30 ug) ,Freund's incomplete adjuvant (100 ul) ,,,,,,, 837,"Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,female,112 days to 65 days,12,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,14.8,d,2.396,8.3,MMO:0000163,in vivo visual assessment,,0.0,,,,,myelin oligodendrocyte glycoprotein (15-20 ug) and Freund's incomplete adjuvant (100 ul) ,69491,myelin oligodendrocyte glycoprotein (15-20 ug) ,Freund's incomplete adjuvant (100 ul) ,,,,,,, 837,"Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716.",central nervous system integrity trait,,RS:0002506,DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini,female,112 days to 65 days,13,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,22.5,d,3.5778,12.9,MMO:0000163,in vivo visual assessment,,0.0,,,,,myelin oligodendrocyte glycoprotein (15-20 ug) and Freund's incomplete adjuvant (100 ul) ,69492,myelin oligodendrocyte glycoprotein (15-20 ug) ,Freund's incomplete adjuvant (100 ul) ,,,,,,, 837,"Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,male,112 days to 65 days,22,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,19.6,d,2.2173,10.4,MMO:0000163,in vivo visual assessment,,0.0,,,,,myelin oligodendrocyte glycoprotein (30 ug) and Freund's incomplete adjuvant (100 ul) ,69493,myelin oligodendrocyte glycoprotein (30 ug) ,Freund's incomplete adjuvant (100 ul) ,,,,,,, 837,"Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716.",central nervous system integrity trait,,RS:0002506,DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini,male,112 days to 65 days,21,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,21.9,d,2.4659,11.3,MMO:0000163,in vivo visual assessment,,0.0,,,,,myelin oligodendrocyte glycoprotein (30 ug) and Freund's incomplete adjuvant (100 ul) ,69494,myelin oligodendrocyte glycoprotein (30 ug) ,Freund's incomplete adjuvant (100 ul) ,,,,,,, 837,"Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,female,112 days to 91 days,N/A,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,89,%,,33.0,MMO:0000163,in vivo visual assessment,,0.0,visual observation,,,,myelin oligodendrocyte glycoprotein (0.09 ug/g) and Freund's incomplete adjuvant (100 ul) ,69497,myelin oligodendrocyte glycoprotein (0.09 ug/g) ,Freund's incomplete adjuvant (100 ul) ,,,,,,, 837,"Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716.",central nervous system integrity trait,,RS:0002506,DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini,female,112 days to 91 days,N/A,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,69,%,,48.0,MMO:0000163,in vivo visual assessment,,0.0,visual observation,,,,myelin oligodendrocyte glycoprotein (0.1 ug/g) and Freund's incomplete adjuvant (100 ul) ,69498,myelin oligodendrocyte glycoprotein (0.1 ug/g) ,Freund's incomplete adjuvant (100 ul) ,,,,,,, 837,"Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,female,112 days to 65 days,N/A,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,15.6,d,,9.4,MMO:0000163,in vivo visual assessment,,0.0,,,,,myelin oligodendrocyte glycoprotein (0.09 ug/g) and Freund's incomplete adjuvant (100 ul) ,69499,myelin oligodendrocyte glycoprotein (0.09 ug/g) ,Freund's incomplete adjuvant (100 ul) ,,,,,,, 837,"Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716.",central nervous system integrity trait,,RS:0002506,DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini,female,112 days to 65 days,N/A,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,22.5,d,,12.9,MMO:0000163,in vivo visual assessment,,0.0,,,,,myelin oligodendrocyte glycoprotein (0.1 ug/g) and Freund's incomplete adjuvant (100 ul) ,69500,myelin oligodendrocyte glycoprotein (0.1 ug/g) ,Freund's incomplete adjuvant (100 ul) ,,,,,,, 837,"Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,female,112 days to 65 days,N/A,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,,,20,d,,8.5,MMO:0000163,in vivo visual assessment,,0.0,,,,,myelin oligodendrocyte glycoprotein (0.09 ug/g) and Freund's incomplete adjuvant (100 ul) ,69501,myelin oligodendrocyte glycoprotein (0.09 ug/g) ,Freund's incomplete adjuvant (100 ul) ,,,,,,, 837,"Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716.",central nervous system integrity trait,,RS:0002506,DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini,female,112 days to 65 days,N/A,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,,,10.1,d,,9.5,MMO:0000163,in vivo visual assessment,,0.0,,,,,myelin oligodendrocyte glycoprotein (0.1 ug/g) and Freund's incomplete adjuvant (100 ul) ,69502,myelin oligodendrocyte glycoprotein (0.1 ug/g) ,Freund's incomplete adjuvant (100 ul) ,,,,,,, 837,"Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,female,112 days to 91 days,12,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,92,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,myelin oligodendrocyte glycoprotein (15-22 ug) and Freund's incomplete adjuvant (100 ul) ,68122,myelin oligodendrocyte glycoprotein (15-22 ug) ,Freund's incomplete adjuvant (100 ul) ,,,,,,, 837,"Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716.",central nervous system integrity trait,,RS:0002506,DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini,female,112 days to 91 days,13,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,69,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,myelin oligodendrocyte glycoprotein (15-22 ug) and Freund's incomplete adjuvant (100 ul) ,68123,myelin oligodendrocyte glycoprotein (15-22 ug) ,Freund's incomplete adjuvant (100 ul) ,,,,,,, 837,"Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,female,112 days to 65 days,12,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,,,19.7,d,2.4826,8.6,MMO:0000163,in vivo visual assessment,,0.0,,,,,myelin oligodendrocyte glycoprotein (15-20 ug) and Freund's incomplete adjuvant (100 ul) ,69376,myelin oligodendrocyte glycoprotein (15-20 ug) ,Freund's incomplete adjuvant (100 ul) ,,,,,,, 837,"Stridh P, et al., PLoS One. 2010 Sep 15;5(9):e12716.",central nervous system integrity trait,,RS:0002506,DA.PVG.1AV1-(D17Rat8-D17Rat37)/Kini,female,112 days to 65 days,13,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,,,10.1,d,2.6348,9.5,MMO:0000163,in vivo visual assessment,,0.0,,,,,myelin oligodendrocyte glycoprotein (15-20 ug) and Freund's incomplete adjuvant (100 ul) ,69377,myelin oligodendrocyte glycoprotein (15-20 ug) ,Freund's incomplete adjuvant (100 ul) ,,,,,,, 838,"Jagodic M, et al., J Immunol 2005 Jan 15;174(2):918-24.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,both,150 days to 63 days,20,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,60,%,,,MMO:0000163,in vivo visual assessment,,0.0,from p.i. day 7,intradermal injection,,,myelin oligodendrocyte glycoprotein (20 ug/200 ul) ,68124,myelin oligodendrocyte glycoprotein (20 ug/200 ul) ,,,,,,,, 838,"Jagodic M, et al., J Immunol 2005 Jan 15;174(2):918-24.",central nervous system integrity trait,,RS:0003524,DA.PVG.1AV1-(D4Got126-D4Got136),both,150 days to 63 days,19,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,DA.PVG.1AV1-(D4Got128-D4Got136) for strain,,10,%,,,MMO:0000163,in vivo visual assessment,,0.0,from p.i. day 7,intradermal injection,,,myelin oligodendrocyte glycoprotein (20 ug/200 ul) ,68126,myelin oligodendrocyte glycoprotein (20 ug/200 ul) ,,,,,,,, 838,"Jagodic M, et al., J Immunol 2005 Jan 15;174(2):918-24.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,both,150 days to 63 days,23,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,from p.i. day 7,intradermal injection,,,myelin oligodendrocyte glycoprotein (20 ug/200 ul) ,68128,myelin oligodendrocyte glycoprotein (20 ug/200 ul) ,,,,,,,, 838,"Jagodic M, et al., J Immunol 2005 Jan 15;174(2):918-24.",central nervous system integrity trait,,RS:0003524,DA.PVG.1AV1-(D4Got126-D4Got136),both,150 days to 63 days,21,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,DA.PVG.1AV1-(D4Got128-D4Got136) for strain,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,from p.i. day 7,intradermal injection,,,myelin oligodendrocyte glycoprotein (20 ug/200 ul) ,68130,myelin oligodendrocyte glycoprotein (20 ug/200 ul) ,,,,,,,, 839,"Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,male,131 days to 103 days,10,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,80,%,,,MMO:0000163,in vivo visual assessment,,0.0,from p.i. day 7,intradermal injection,40,days,myelin oligodendrocyte glycoprotein (20 ug) ,68706,myelin oligodendrocyte glycoprotein (20 ug) ,,,,,,,, 839,"Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,male,131 days to 103 days,8,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,16.2,d,0.9192,2.6,MMO:0000163,in vivo visual assessment,,0.0,from p.i. day 7,intradermal injection,,,myelin oligodendrocyte glycoprotein (20 ug) ,68707,myelin oligodendrocyte glycoprotein (20 ug) ,,,,,,,, 839,"Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,male,131 days to 103 days,8,,CMO:0001402,percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time,,,,87.5,%,,,MMO:0000163,in vivo visual assessment,,0.0,from p.i. day 7,intradermal injection,40,days,myelin oligodendrocyte glycoprotein (20 ug) ,68709,myelin oligodendrocyte glycoprotein (20 ug) ,,,,,,,, 839,"Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,male,131 days to 103 days,12,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,50,%,,,MMO:0000163,in vivo visual assessment,,0.0,from p.i. day 7,intradermal injection,40,days,myelin oligodendrocyte glycoprotein (20 ug) ,68710,myelin oligodendrocyte glycoprotein (20 ug) ,,,,,,,, 839,"Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,male,131 days to 103 days,6,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,21.2,d,0.5307,1.3,MMO:0000163,in vivo visual assessment,,0.0,from p.i. day 7,intradermal injection,,,myelin oligodendrocyte glycoprotein (20 ug) ,68711,myelin oligodendrocyte glycoprotein (20 ug) ,,,,,,,, 839,"Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,male,131 days to 103 days,6,,CMO:0001402,percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time,,CMO:0001402,,50,%,,,MMO:0000163,in vivo visual assessment,,0.0,from p.i. day 7,intradermal injection,40,days,myelin oligodendrocyte glycoprotein (20 ug) ,68713,myelin oligodendrocyte glycoprotein (20 ug) ,,,,,,,, 839,"Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,male,131 days to 103 days,10,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,80,%,,,MMO:0000163,in vivo visual assessment,,0.0,from p.i. day 7,intradermal injection,40,days,myelin oligodendrocyte glycoprotein (20 ug) ,68714,myelin oligodendrocyte glycoprotein (20 ug) ,,,,,,,, 839,"Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,male,131 days to 103 days,8,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,19.2,d,1.2374,3.5,MMO:0000163,in vivo visual assessment,,0.0,from p.i. day 7,intradermal injection,,,myelin oligodendrocyte glycoprotein (20 ug) ,68715,myelin oligodendrocyte glycoprotein (20 ug) ,,,,,,,, 839,"Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,male,131 days to 103 days,8,,CMO:0001402,percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time,,,,87.5,%,,,MMO:0000163,in vivo visual assessment,,0.0,from p.i. day 7,intradermal injection,40,days,myelin oligodendrocyte glycoprotein (20 ug) ,68717,myelin oligodendrocyte glycoprotein (20 ug) ,,,,,,,, 839,"Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5.",central nervous system integrity trait,,RS:0000199,DA.ACI-(D10Rat2-D10Rat29)/Kini,male,131 days to 103 days,10,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,30,%,,,MMO:0000163,in vivo visual assessment,,0.0,from p.i. day 7,intradermal injection,40,days,myelin oligodendrocyte glycoprotein (20 ug) ,68718,myelin oligodendrocyte glycoprotein (20 ug) ,,,,,,,, 839,"Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5.",central nervous system integrity trait,,RS:0000199,DA.ACI-(D10Rat2-D10Rat29)/Kini,male,131 days to 103 days,3,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,14.7,d,1.4434,2.5,MMO:0000163,in vivo visual assessment,,0.0,from p.i. day 7,intradermal injection,,,myelin oligodendrocyte glycoprotein (20 ug) ,68719,myelin oligodendrocyte glycoprotein (20 ug) ,,,,,,,, 839,"Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5.",central nervous system integrity trait,,RS:0000199,DA.ACI-(D10Rat2-D10Rat29)/Kini,male,131 days to 103 days,3,,CMO:0001402,percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,from p.i. day 7,intradermal injection,40,days,myelin oligodendrocyte glycoprotein (20 ug) ,68721,myelin oligodendrocyte glycoprotein (20 ug) ,,,,,,,, 839,"Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5.",central nervous system integrity trait,,RS:0000199,DA.ACI-(D10Rat2-D10Rat29)/Kini,male,131 days to 103 days,10,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,from p.i. day 7,intradermal injection,40,days,myelin oligodendrocyte glycoprotein (20 ug) ,68722,myelin oligodendrocyte glycoprotein (20 ug) ,,,,,,,, 839,"Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5.",central nervous system integrity trait,,RS:0000199,DA.ACI-(D10Rat2-D10Rat29)/Kini,male,131 days to 103 days,8,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,from p.i. day 7,intradermal injection,40,days,myelin oligodendrocyte glycoprotein (20 ug) ,68724,myelin oligodendrocyte glycoprotein (20 ug) ,,,,,,,, 839,"Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5.",central nervous system integrity trait,,RS:0000199,DA.ACI-(D10Rat2-D10Rat29)/Kini,male,131 days to 103 days,7,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,14,%,,,MMO:0000163,in vivo visual assessment,,0.0,from p.i. day 7,intradermal injection,40,days,myelin oligodendrocyte glycoprotein (20 ug) ,68726,myelin oligodendrocyte glycoprotein (20 ug) ,,,,,,,, 839,"Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5.",central nervous system integrity trait,,RS:0000199,DA.ACI-(D10Rat2-D10Rat29)/Kini,male,131 days to 103 days,1,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,23,d,,,MMO:0000163,in vivo visual assessment,,0.0,from p.i. day 7,intradermal injection,,,myelin oligodendrocyte glycoprotein (20 ug) ,68727,myelin oligodendrocyte glycoprotein (20 ug) ,,,,,,,, 839,"Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5.",central nervous system integrity trait,,RS:0000199,DA.ACI-(D10Rat2-D10Rat29)/Kini,male,131 days to 103 days,1,,CMO:0001402,percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,from p.i. day 7,intradermal injection,40,days,myelin oligodendrocyte glycoprotein (20 ug) ,68729,myelin oligodendrocyte glycoprotein (20 ug) ,,,,,,,, 839,"Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,male,131 days to 103 days,11,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,from p.i. day 7,intradermal injection,40,days,myelin oligodendrocyte glycoprotein (20 ug) ,68132,myelin oligodendrocyte glycoprotein (20 ug) ,,,,,,,, 839,"Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,male,131 days to 103 days,11,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,14.9,d,1.0251,3.4,MMO:0000163,in vivo visual assessment,,0.0,from p.i. day 7,intradermal injection,,,myelin oligodendrocyte glycoprotein (20 ug) ,68133,myelin oligodendrocyte glycoprotein (20 ug) ,,,,,,,, 839,"Jagodic M, et al., Immunogenetics 2001 Jul;53(5):410-5.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,male,131 days to 103 days,11,,CMO:0001402,percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time,,CMO:0001402,,91,%,,,MMO:0000163,in vivo visual assessment,,0.0,from p.i. day 7,intradermal injection,40,days,myelin oligodendrocyte glycoprotein (20 ug) ,68135,myelin oligodendrocyte glycoprotein (20 ug) ,,,,,,,, 850,"Griffiths MM, et al., Arthritis Rheum 2000 Jun;43(6):1278-89",joint integrity trait,,RS:0000239,DA/Bkl,both,126 days to 66 days,105,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,variable,immunized,10,days,type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) ,69959,type II collagen (2 mg/kg) ,Freund's incomplete adjuvant (50 %) ,,,,,,, 850,"Griffiths MM, et al., Arthritis Rheum 2000 Jun;43(6):1278-89",joint integrity trait,,RS:0000154,BN/SsN,both,126 days to 66 days,13,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,variable,immunized,10,days,type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) ,69961,type II collagen (2 mg/kg) ,Freund's incomplete adjuvant (50 %) ,,,,,,, 850,"Griffiths MM, et al., Arthritis Rheum 2000 Jun;43(6):1278-89",joint integrity trait,,RS:0000239,DA/Bkl,both,126 days to 66 days,105,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,15,d,0.1952,2.0,MMO:0000163,in vivo visual assessment,,0.0,variable,immunized,10,days,type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) ,68143,type II collagen (2 mg/kg) ,Freund's incomplete adjuvant (50 %) ,,,,,,, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,female,0 days,28,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,64,%,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 37 days,subcutaneous injection,37,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 37 days),69378,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 37 days),,,,,,,, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002390,DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini,female,0 days,24,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,33,%,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to38 days,subcutaneous injection,37,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days),69379,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days),,,,,,,, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,female,0 days,28,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,26.5,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 37 days,subcutaneous injection,,,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 37 days),69380,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 37 days),,,,,,,, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,female,0 days,28,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,days,,10.7,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 37 days,subcutaneous injection,37,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 37 days),69381,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 37 days),,,,,,,, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002390,DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini,female,0 days,24,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,33,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to38 days,subcutaneous injection,,,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days),69382,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days),,,,,,,, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002390,DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini,female,0 days,24,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,days,,5.5,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to38 days,subcutaneous injection,37,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days),69383,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days),,,,,,,, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,female,0 days,16,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,50,%,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 40 days,subcutaneous injection,40,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days),69384,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days),,,,,,,, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,female,0 days,16,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,33.8,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 40 days,subcutaneous injection,,,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days),69385,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days),,,,,,,, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,female,0 days,16,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,days,,6.8,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 40 days,subcutaneous injection,40,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days),69386,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days),,,,,,,, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002389,DA.PVG.1AV1-(D4Got211-D4Mit12)/Kini,female,0 days,16,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,38,%,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 40 days,subcutaneous injection,40,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days),69387,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days),,,,,,,, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002389,DA.PVG.1AV1-(D4Got211-D4Mit12)/Kini,female,0 days,16,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,33.9,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 40 days,subcutaneous injection,,,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days),69388,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days),,,,,,,, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002389,DA.PVG.1AV1-(D4Got211-D4Mit12)/Kini,female,0 days,16,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,days,,4.9,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 40 days,subcutaneous injection,40,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days),69389,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days),,,,,,,, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,female,0 days,18,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,94,%,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 38 days,subcutaneous injection,38,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days),69390,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days),,,,,,,, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,female,0 days,18,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,16.7,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 38 days,subcutaneous injection,,,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days),69391,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days),,,,,,,, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,female,0 days,18,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,days,,14.3,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 31 days,subcutaneous injection,31,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days),69392,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days),,,,,,,, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,female,0 days,18,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,days,,20.9,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 38 days,subcutaneous injection,38,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days),69393,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days),,,,,,,, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002385,DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini,female,0 days,10,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,90,%,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 31days,subcutaneous injection,31,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days),69394,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days),,,,,,,, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002385,DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini,female,0 days,10,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,18.2,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 31days,subcutaneous injection,,,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days),69395,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days),,,,,,,, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002385,DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini,female,0 days,10,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,days,,22.6,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 31days,subcutaneous injection,31,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days),69396,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days),,,,,,,, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002389,DA.PVG.1AV1-(D4Got211-D4Mit12)/Kini,female,0 days,19,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 31days,subcutaneous injection,31,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days),69397,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days),,,,,,,, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002389,DA.PVG.1AV1-(D4Got211-D4Mit12)/Kini,female,0 days,19,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,days,,15.8,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 31days,subcutaneous injection,,,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days),69398,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days),,,,,,,, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002389,DA.PVG.1AV1-(D4Got211-D4Mit12)/Kini,female,0 days,19,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,days,,11.8,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 31days,subcutaneous injection,31,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days),69399,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 31 days),,,,,,,, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002390,DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini,female,0 days,11,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,91,%,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 38days,subcutaneous injection,38,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days),69406,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days),,,,,,,, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002390,DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini,female,0 days,11,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,17.4,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 38days,subcutaneous injection,,,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days),69407,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days),,,,,,,, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002390,DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini,female,0 days,11,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,,,17.6,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 38days,subcutaneous injection,38,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days),69408,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 38 days),,,,,,,, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,female,0 days,10,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 40 days,subcutaneous injection,40,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days),69409,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days),,,,,,,, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,female,0 days,10,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,14.1,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 40 days,subcutaneous injection,,,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days),69410,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days),,,,,,,, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,female,0 days,10,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,,,23.8,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 40 days,subcutaneous injection,40,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days),69411,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days),,,,,,,, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002385,DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini,female,0 days,7,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 40 days,subcutaneous injection,40,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days),69412,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days),,,,,,,, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002385,DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini,female,0 days,7,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,16.3,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 40 days,subcutaneous injection,,,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days),69413,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days),,,,,,,, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002385,DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini,female,0 days,7,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,,,22.4,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 40 days,subcutaneous injection,40,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days),69414,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days),,,,,,,, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002386,DA.PVG.1AV1-(D4Rat23-D4Mit12)/Kini,female,0 days,14,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,86,%,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 40 days,subcutaneous injection,40,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days),69415,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days),,,,,,,, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002386,DA.PVG.1AV1-(D4Rat23-D4Mit12)/Kini,female,0 days,14,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,11.2,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 40 days,subcutaneous injection,,,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days),69416,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days),,,,,,,, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002386,DA.PVG.1AV1-(D4Rat23-D4Mit12)/Kini,female,0 days,14,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,,,18.4,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 40 days,subcutaneous injection,40,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days),69417,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 40 days),,,,,,,, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,female,0 days,21,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,18.7,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 28 days,subcutaneous injection,,,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days),69418,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days),,,,,,,, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,female,0 days,21,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,,,11.5,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 28 days,subcutaneous injection,28,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days),69419,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days),,,,,,,, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002387,DA.PVG.1AV1-(D4Rat103-D4Mit12)/Kini,female,0 days,19,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,17.3,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 28 days,subcutaneous injection,,,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days),69420,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days),,,,,,,, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002387,DA.PVG.1AV1-(D4Rat103-D4Mit12)/Kini,female,0 days,19,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,,,11.2,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 28 days,subcutaneous injection,28,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days),69421,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days),,,,,,,, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002388,DA.PVG.1AV1-(D4Rat231-D4Mit12)/Kini,female,0 days,21,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,16.2,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 28 days,subcutaneous injection,,,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days),69422,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days),,,,,,,, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002388,DA.PVG.1AV1-(D4Rat231-D4Mit12)/Kini,female,0 days,21,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,,,13.3,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 28 days,subcutaneous injection,28,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days),69423,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 28 days),,,,,,,, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,female,0 days,17,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,25.2,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 34 days,subcutaneous injection,,,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days),69424,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days),,,,,,,, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0001858,DA/ZtmKini,female,0 days,17,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,,,9,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 34 days,subcutaneous injection,34,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days),69425,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days),,,,,,,, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002385,DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini,female,0 days,10,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,30,%,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 34 days,subcutaneous injection,34,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days),69426,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days),,,,,,,, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002385,DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini,female,0 days,10,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,32.8,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 34 days,subcutaneous injection,,,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days),69427,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days),,,,,,,, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002385,DA.PVG.1AV1-(D4Rat23-D4Rat108)/Kini,female,0 days,10,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,,,2.7,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 34 days,subcutaneous injection,34,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days),69428,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days),,,,,,,, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002386,DA.PVG.1AV1-(D4Rat23-D4Mit12)/Kini,female,0 days,18,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,31.2,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 34 days,subcutaneous injection,,,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days),69429,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days),,,,,,,, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002386,DA.PVG.1AV1-(D4Rat23-D4Mit12)/Kini,female,0 days,18,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,,,6,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 34 days,subcutaneous injection,34,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days),69430,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days),,,,,,,, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002387,DA.PVG.1AV1-(D4Rat103-D4Mit12)/Kini,female,0 days,9,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,28.4,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 34 days,subcutaneous injection,,,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days),69431,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days),,,,,,,, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002387,DA.PVG.1AV1-(D4Rat103-D4Mit12)/Kini,female,0 days,9,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,,,5.9,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 34 days,subcutaneous injection,34,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days),69432,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days),,,,,,,, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002388,DA.PVG.1AV1-(D4Rat231-D4Mit12)/Kini,female,0 days,14,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,28.9,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 34 days,subcutaneous injection,,,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days),69433,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days),,,,,,,, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002388,DA.PVG.1AV1-(D4Rat231-D4Mit12)/Kini,female,0 days,14,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,,,7.8,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 34 days,subcutaneous injection,34,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days),69434,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days),,,,,,,, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002390,DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini,female,0 days,6,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,50,%,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 34 days,subcutaneous injection,34,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days),69435,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days),,,,,,,, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002390,DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini,female,0 days,6,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,28.3,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 34 days,subcutaneous injection,,,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days),69436,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days),,,,,,,, 892,"Marta M, et al., Genes Immun. 2010 Jan;11(1):21-36. Epub 2009 Aug 13.",central nervous system integrity trait,,RS:0002390,DA.PVG.1AV1-(D4Got60-D4Kini1)/Kini,female,0 days,6,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,,,7.5,d,,,MMO:0000163,in vivo visual assessment,,0.0,from 8 to 34 days,subcutaneous injection,34,days,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days),69437,myelin oligodendrocyte glycoprotein (13-85 ug/200 ul) (for 34 days),,,,,,,, 1076,"Zidek V, et al., J Reprod Fertil 1999 Jul;116(2):329-33.",single birth offspring quantity,,RS:0000715,SHR/OlaIpcv,male,90 days,9,,CMO:0000642,litter size,,,,7.6,,0.7333,2.2,MMO:0000163,in vivo visual assessment,,0.0,,,,,control condition,69023,control condition,,,,,,,, 1076,"Zidek V, et al., J Reprod Fertil 1999 Jul;116(2):329-33.",single birth offspring quantity,,RS:0000116,BN-Lx/Cub,male,90 days,9,,CMO:0000642,litter size,,,,4.5,,0.6333,1.9,MMO:0000163,in vivo visual assessment,,0.0,,,,,control condition,69024,control condition,,,,,,,, 1258,"Bergsteinsdottir K, et al., J Immunol 2000 Feb 1;164(3):1564-8",central nervous system integrity trait,,RS:0000242,DA/Ztm,male,103 days to 56 days,9,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,,,9,d,2.6667,8.0,MMO:0000163,in vivo visual assessment,,0.0,,,,,spinal cord homogenate (10 mg) ,69953,spinal cord homogenate (10 mg) ,,,,,,,, 1258,"Bergsteinsdottir K, et al., J Immunol 2000 Feb 1;164(3):1564-8",central nervous system integrity trait,,RS:0000261,E3/Ztm,male,103 days to 56 days,3,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,spinal cord homogenate (10 mg) ,69954,spinal cord homogenate (10 mg) ,,,,,,,, 1258,"Bergsteinsdottir K, et al., J Immunol 2000 Feb 1;164(3):1564-8",central nervous system integrity trait,,RS:0000261,E3/Ztm,female,103 days to 56 days,12,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,spinal cord homogenate (10 mg) ,69955,spinal cord homogenate (10 mg) ,,,,,,,, 1258,"Bergsteinsdottir K, et al., J Immunol 2000 Feb 1;164(3):1564-8",central nervous system integrity trait,,RS:0000242,DA/Ztm,male,103 days to 56 days,9,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,78,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,spinal cord homogenate (10 mg) ,69949,spinal cord homogenate (10 mg) ,,,,,,,, 1258,"Bergsteinsdottir K, et al., J Immunol 2000 Feb 1;164(3):1564-8",central nervous system integrity trait,,RS:0000242,DA/Ztm,male,103 days to 56 days,9,,CMO:0001859,percentage of study population developing acute experimental autoimmune encephalomyelitis during a period of time,,,,22,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,spinal cord homogenate (10 mg) ,69950,spinal cord homogenate (10 mg) ,,,,,,,, 1258,"Bergsteinsdottir K, et al., J Immunol 2000 Feb 1;164(3):1564-8",central nervous system integrity trait,,RS:0000242,DA/Ztm,male,103 days to 56 days,9,,CMO:0001402,percentage of study population developing relapsing-remitting experimental autoimmune encephalomyelitis during a period of time,,,,56,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,spinal cord homogenate (10 mg) ,69951,spinal cord homogenate (10 mg) ,,,,,,,, 1258,"Bergsteinsdottir K, et al., J Immunol 2000 Feb 1;164(3):1564-8",central nervous system integrity trait,,RS:0000242,DA/Ztm,male,103 days to 56 days,9,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,13,d,2.0,6.0,MMO:0000163,in vivo visual assessment,,0.0,,,,,spinal cord homogenate (10 mg) ,69952,spinal cord homogenate (10 mg) ,,,,,,,, 1239,"Yokoyama M, et al., Mamm Genome 2001 Mar;12(3):207-11.",lens clarity trait,,RS:0000405,IER/Ihr,female,120 days to 0 days,70,,CMO:0001586,percentage of study population developing cataract during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,control condition,69906,control condition,,,,,,,, 1239,"Yokoyama M, et al., Mamm Genome 2001 Mar;12(3):207-11.",lens clarity trait,,RS:0000405,IER/Ihr,male,120 days to 0 days,73,,CMO:0001586,percentage of study population developing cataract during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,control condition,69907,control condition,,,,,,,, 1159,"Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83",joint integrity trait,,RS:0000513,LEW/Han,both,98 days to 56 days,11,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,82,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69660,pristane (150 ul) ,,,,,,,, 1159,"Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83",joint integrity trait,,RS:0000497,LEW.1F,both,98 days to 56 days,10,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69661,pristane (150 ul) ,,,,,,,, 1159,"Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83",joint integrity trait,,RS:0002062,LEW.1N,both,98 days to 56 days,11,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,64,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69662,pristane (150 ul) ,,,,,,,, 1159,"Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83",joint integrity trait,,RS:0001675,DA/ZtmRhd,both,98 days to 56 days,17,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69663,pristane (150 ul) ,,,,,,,, 1159,"Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83",joint integrity trait,,RS:0000208,E3/ZtmRhd,both,98 days to 56 days,23,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,9,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69664,pristane (150 ul) ,,,,,,,, 1159,"Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83",joint integrity trait,,RS:0000382,DXE1/Ztm,both,98 days to 56 days,20,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,70,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69665,pristane (150 ul) ,,,,,,,, 1159,"Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83",joint integrity trait,,RS:0000383,DXE2/Ztm,both,98 days to 56 days,24,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,33,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69666,pristane (150 ul) ,,,,,,,, 1159,"Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83",joint integrity trait,,RS:0000384,DXE3/Ztm,both,98 days to 56 days,20,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,10,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69667,pristane (150 ul) ,,,,,,,, 1159,"Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83",joint integrity trait,,RS:0000513,LEW/Han,both,98 days to 56 days,11,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,23,d,3.0151,10.0,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69668,pristane (150 ul) ,,,,,,,, 1159,"Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83",joint integrity trait,,RS:0000497,LEW.1F,both,98 days to 56 days,10,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,17,d,1.2649,4.0,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69669,pristane (150 ul) ,,,,,,,, 1159,"Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83",joint integrity trait,,RS:0002062,LEW.1N,both,98 days to 56 days,11,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,21,d,2.1106,7.0,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69670,pristane (150 ul) ,,,,,,,, 1159,"Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83",joint integrity trait,,RS:0001675,DA/ZtmRhd,both,98 days to 56 days,17,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,14,d,0.4851,2.0,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69671,pristane (150 ul) ,,,,,,,, 1159,"Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83",joint integrity trait,,RS:0000208,E3/ZtmRhd,both,98 days to 56 days,23,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,38,d,1.2511,6.0,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69672,pristane (150 ul) ,,,,,,,, 1159,"Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83",joint integrity trait,,RS:0000382,DXE1/Ztm,both,98 days to 56 days,20,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,31,d,4.6957,21.0,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69673,pristane (150 ul) ,,,,,,,, 1159,"Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83",joint integrity trait,,RS:0000383,DXE2/Ztm,both,98 days to 56 days,24,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,72,d,6.9402,34.0,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69674,pristane (150 ul) ,,,,,,,, 1159,"Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83",joint integrity trait,,RS:0000384,DXE3/Ztm,both,98 days to 56 days,20,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,32,d,3.3541,15.0,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69675,pristane (150 ul) ,,,,,,,, 1159,"Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83",joint integrity trait,,RS:0000513,LEW/Han,both,98 days to 56 days,11,,CMO:0001456,percentage of study population developing chronic experimental arthritis during a period of time,,,,82,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69676,pristane (150 ul) ,,,,,,,, 1159,"Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83",joint integrity trait,,RS:0000497,LEW.1F,both,98 days to 56 days,10,,CMO:0001456,percentage of study population developing chronic experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69677,pristane (150 ul) ,,,,,,,, 1159,"Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83",joint integrity trait,,RS:0002062,LEW.1N,both,98 days to 56 days,11,,CMO:0001456,percentage of study population developing chronic experimental arthritis during a period of time,,,,54,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69678,pristane (150 ul) ,,,,,,,, 1159,"Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83",joint integrity trait,,RS:0001675,DA/ZtmRhd,both,98 days to 56 days,17,,CMO:0001456,percentage of study population developing chronic experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69679,pristane (150 ul) ,,,,,,,, 1159,"Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83",joint integrity trait,,RS:0000208,E3/ZtmRhd,both,98 days to 56 days,23,,CMO:0001456,percentage of study population developing chronic experimental arthritis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69680,pristane (150 ul) ,,,,,,,, 1159,"Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83",joint integrity trait,,RS:0000382,DXE1/Ztm,both,98 days to 56 days,20,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,10,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69681,pristane (150 ul) ,,,,,,,, 1159,"Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83",joint integrity trait,,RS:0000383,DXE2/Ztm,both,98 days to 56 days,24,,CMO:0001456,percentage of study population developing chronic experimental arthritis during a period of time,,,,30,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69682,pristane (150 ul) ,,,,,,,, 1159,"Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83",joint integrity trait,,RS:0000384,DXE3/Ztm,both,98 days to 56 days,20,,CMO:0001456,percentage of study population developing chronic experimental arthritis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69683,pristane (150 ul) ,,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",stillborn offspring quantity,,RS:0001592,HanTac:WH,female,0 days,18,,CMO:0002383,number of fetuses lost perinatally to litter size ratio,,,,8.5,%,1.8856,8.0,MMO:0000163,in vivo visual assessment,,0.0,,,,,vehicle control condition (for 14 days),96592,vehicle control condition (for 14 days),,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",stillborn offspring quantity,,RS:0001592,HanTac:WH,female,0 days,21,,CMO:0002383,number of fetuses lost perinatally to litter size ratio,,,,10.8,%,2.7059,12.4,MMO:0000163,in vivo visual assessment,,0.0,,,,,bisphenol A (0.025 mg/kg/d) (for 14 days),96593,bisphenol A (0.025 mg/kg/d) (for 14 days),,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",stillborn offspring quantity,,RS:0001592,HanTac:WH,female,0 days,17,,CMO:0002383,number of fetuses lost perinatally to litter size ratio,,,,9.2,%,1.916,7.9,MMO:0000163,in vivo visual assessment,,0.0,,,,,bisphenol A (0.25 mg/kg/d) (for 14 days),96594,bisphenol A (0.25 mg/kg/d) (for 14 days),,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",stillborn offspring quantity,,RS:0001592,HanTac:WH,female,0 days,18,,CMO:0002383,number of fetuses lost perinatally to litter size ratio,,,,6.8,%,1.2728,5.4,MMO:0000163,in vivo visual assessment,,0.0,,,,,bisphenol A (5 mg/kg/d) (for 14 days),96595,bisphenol A (5 mg/kg/d) (for 14 days),,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",stillborn offspring quantity,,RS:0001592,HanTac:WH,female,0 days,18,,CMO:0002383,number of fetuses lost perinatally to litter size ratio,,,,17.9,%,6.2461,26.5,MMO:0000163,in vivo visual assessment,,0.0,,,,,bisphenol A (50 mg/kg/d) (for 14 days),96596,bisphenol A (50 mg/kg/d) (for 14 days),,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",total life span,,RS:0001592,HanTac:WH,female,0 days,18,,CMO:0002384,number of perinatal live-born offspring deaths to litter size ratio,,,,3.2,%,1.2728,5.4,MMO:0000163,in vivo visual assessment,,0.0,,,,,vehicle control condition (for 14 days),96602,vehicle control condition (for 14 days),,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",total life span,,RS:0001592,HanTac:WH,female,0 days,21,,CMO:0002384,number of perinatal live-born offspring deaths to litter size ratio,,,,3.3,%,1.5712,7.2,MMO:0000163,in vivo visual assessment,,0.0,,,,,bisphenol A (0.025 mg/kg/d) (for 14 days),96603,bisphenol A (0.025 mg/kg/d) (for 14 days),,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",single birth offspring quantity,,RS:0001592,HanTac:WH,female,0 days,17,,CMO:0002494,number of male offspring to litter size ratio,,,,45.1,%,5.4571,22.5,MMO:0000163,in vivo visual assessment,,0.0,,,,,bisphenol A (0.25 mg/kg/d) (for 14 days),96609,bisphenol A (0.25 mg/kg/d) (for 14 days),,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",gestation period duration,,RS:0001592,HanTac:WH,female,0 days,18,,CMO:0000467,gestation period length,,,,23,d,0.1414,0.6,MMO:0000163,in vivo visual assessment,,0.0,,,,,vehicle control condition (for 14 days),96583,vehicle control condition (for 14 days),,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",gestation period duration,,RS:0001592,HanTac:WH,female,0 days,21,,CMO:0000467,gestation period length,,,,22.9,d,0.0786,0.36,MMO:0000163,in vivo visual assessment,,0.0,,,,,bisphenol A (0.025 mg/kg/d) (for 14 days),96584,bisphenol A (0.025 mg/kg/d) (for 14 days),,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",gestation period duration,,RS:0001592,HanTac:WH,female,0 days,18,,CMO:0000467,gestation period length,,,,22.9,d,0.0471,0.2,MMO:0000163,in vivo visual assessment,,0.0,,,,,bisphenol A (5 mg/kg/d) (for 14 days),96585,bisphenol A (5 mg/kg/d) (for 14 days),,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",single birth offspring quantity,,RS:0001592,HanTac:WH,female,0 days,18,,CMO:0000642,litter size,,,,11.8,,0.7778,3.3,MMO:0000163,in vivo visual assessment,,0.0,,,,,vehicle control condition (for 14 days),96597,vehicle control condition (for 14 days),,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",single birth offspring quantity,,RS:0001592,HanTac:WH,female,0 days,21,,CMO:0000642,litter size,,,,11.7,,0.5019,2.3,MMO:0000163,in vivo visual assessment,,0.0,,,,,bisphenol A (0.025 mg/kg/d) (for 14 days),96598,bisphenol A (0.025 mg/kg/d) (for 14 days),,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",single birth offspring quantity,,RS:0001592,HanTac:WH,female,0 days,17,,CMO:0000642,litter size,,,,12.1,,0.8489,3.5,MMO:0000163,in vivo visual assessment,,0.0,,,,,bisphenol A (0.25 mg/kg/d) (for 14 days),96599,bisphenol A (0.25 mg/kg/d) (for 14 days),,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",single birth offspring quantity,,RS:0001592,HanTac:WH,female,0 days,18,,CMO:0000642,litter size,,,,11.4,,0.6128,2.6,MMO:0000163,in vivo visual assessment,,0.0,,,,,bisphenol A (5 mg/kg/d) (for 14 days),96600,bisphenol A (5 mg/kg/d) (for 14 days),,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",single birth offspring quantity,,RS:0001592,HanTac:WH,female,0 days,18,,CMO:0000642,litter size,,,,11.2,,0.9664,4.1,MMO:0000163,in vivo visual assessment,,0.0,,,,,bisphenol A (50 mg/kg/d) (for 14 days),96601,bisphenol A (50 mg/kg/d) (for 14 days),,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",total life span,,RS:0001592,HanTac:WH,female,0 days,17,,CMO:0002384,number of perinatal live-born offspring deaths to litter size ratio,,,,2.5,%,1.1884,4.9,MMO:0000163,in vivo visual assessment,,0.0,,,,,bisphenol A (0.25 mg/kg/d) (for 14 days),96604,bisphenol A (0.25 mg/kg/d) (for 14 days),,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",total life span,,RS:0001592,HanTac:WH,female,0 days,18,,CMO:0002384,number of perinatal live-born offspring deaths to litter size ratio,,,,1,%,0.66,2.8,MMO:0000163,in vivo visual assessment,,0.0,,,,,bisphenol A (5 mg/kg/d) (for 14 days),96605,bisphenol A (5 mg/kg/d) (for 14 days),,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",total life span,,RS:0001592,HanTac:WH,female,0 days,18,,CMO:0002384,number of perinatal live-born offspring deaths to litter size ratio,,,,8.6,%,5.5154,23.4,MMO:0000163,in vivo visual assessment,,0.0,,,,,bisphenol A (50 mg/kg/d) (for 14 days),96606,bisphenol A (50 mg/kg/d) (for 14 days),,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",single birth offspring quantity,,RS:0001592,HanTac:WH,female,0 days,18,,CMO:0002494,number of male offspring to litter size ratio,,(number of males to litter size) ratio),,50.5,%,4.3605,18.5,MMO:0000163,in vivo visual assessment,,0.0,,,,,vehicle control condition (for 14 days),96607,vehicle control condition (for 14 days),,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",single birth offspring quantity,,RS:0001592,HanTac:WH,female,0 days,21,,CMO:0002494,number of male offspring to litter size ratio,,,,49.8,%,3.2078,14.7,MMO:0000163,in vivo visual assessment,,0.0,,,,,bisphenol A (0.025 mg/kg/d) (for 14 days),96608,bisphenol A (0.025 mg/kg/d) (for 14 days),,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",single birth offspring quantity,,RS:0001592,HanTac:WH,female,0 days,18,,CMO:0002494,number of male offspring to litter size ratio,,,,49.7,%,3.6062,15.3,MMO:0000163,in vivo visual assessment,,0.0,,,,,bisphenol A (5 mg/kg/d) (for 14 days),96610,bisphenol A (5 mg/kg/d) (for 14 days),,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",single birth offspring quantity,,RS:0001592,HanTac:WH,female,0 days,18,,CMO:0002494,number of male offspring to litter size ratio,,,,56.2,%,2.4513,10.4,MMO:0000163,in vivo visual assessment,,0.0,,,,,bisphenol A (50 mg/kg/d) (for 14 days),96611,bisphenol A (50 mg/kg/d) (for 14 days),,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",nipple quantity,,RS:0001592,HanTac:WH,male,14 days,17,,CMO:0002386,areola mammae/nipple number,,,,0.1,,0.0485,0.2,MMO:0000163,in vivo visual assessment,,0.0,,,,,vehicle control condition (for 14 days),96627,vehicle control condition (for 14 days),,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",nipple quantity,,RS:0001592,HanTac:WH,male,14 days,17,,CMO:0002386,areola mammae/nipple number,,,,0.2,,0.0728,0.3,MMO:0000163,in vivo visual assessment,,0.0,,,,,bisphenol A (0.025 mg/kg/d) (for 14 days),96628,bisphenol A (0.025 mg/kg/d) (for 14 days),,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",nipple quantity,,RS:0001592,HanTac:WH,male,14 days,17,,CMO:0002386,areola mammae/nipple number,,,,0.2,,0.0485,0.2,MMO:0000163,in vivo visual assessment,,0.0,,,,,bisphenol A (0.25 mg/kg/d) (for 14 days),96629,bisphenol A (0.25 mg/kg/d) (for 14 days),,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",nipple quantity,,RS:0001592,HanTac:WH,male,14 days,17,,CMO:0002386,areola mammae/nipple number,,,,0.3,,0.097,0.4,MMO:0000163,in vivo visual assessment,,0.0,,,,,bisphenol A (5 mg/kg/d) (for 14 days),96630,bisphenol A (5 mg/kg/d) (for 14 days),,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",nipple quantity,,RS:0001592,HanTac:WH,male,14 days,17,,CMO:0002386,areola mammae/nipple number,,,,0.4,,0.1455,0.6,MMO:0000163,in vivo visual assessment,,0.0,,,,,bisphenol A (50 mg/kg/d) (for 14 days),96631,bisphenol A (50 mg/kg/d) (for 14 days),,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",gestation period duration,,RS:0001592,HanTac:WH,female,0 days,17,,CMO:0000467,gestation period length,,,,22.9,d,0.1455,0.6,MMO:0000163,in vivo visual assessment,,0.0,,,,,bisphenol A (0.25 mg/kg/d) (for 14 days),96582,bisphenol A (0.25 mg/kg/d) (for 14 days),,,,,,,, 1559,"Christiansen S, et al., Reproduction. 2014 Mar 2;147(4):477-87. doi: 10.1530/REP-13-0377. Print 2014.",gestation period duration,,RS:0001592,HanTac:WH,female,0 days,18,,CMO:0000467,gestation period length,,,,23,d,0.0707,0.3,MMO:0000163,in vivo visual assessment,,0.0,,,,,bisphenol A (50 mg/kg/d) (for 14 days),96586,bisphenol A (50 mg/kg/d) (for 14 days),,,,,,,, 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0003684,LEW.1AV1.DA-(D4Mgh17-D4Rat203)/Kiru,both,0 days,13,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,15.4,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,70193,Freund's incomplete adjuvant (200 ul) ,,,,,,,, 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0001858,DA/ZtmKini,both,0 days,27,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,14,d,1.0585,5.5,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,70194,Freund's incomplete adjuvant (200 ul) ,,,,,,,, 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0000225,DA.PVG-(D4Rat141-D4Mgh11),both,0 days,30,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,31.7,d,1.8623,10.2,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,70195,Freund's incomplete adjuvant (200 ul) ,,,,,,,, 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0001858,DA/ZtmKini,both,0 days,5,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,12.2,d,0.1789,0.4,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,70196,Freund's incomplete adjuvant (200 ul) ,,,,,,,, 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0000228,DA.PVG.1AV1-(D4Rat155-Spr),both,0 days,12,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,25,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,70197,Freund's incomplete adjuvant (200 ul) ,,,,,,,, 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0000228,DA.PVG.1AV1-(D4Rat155-Spr),both,0 days,12,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,13.7,d,0.433,1.5,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,70198,Freund's incomplete adjuvant (200 ul) ,,,,,,,, 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0000226,DA.PVG.1AV1-(D4Mgh17-D4Rat56),both,0 days,7,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,70199,Freund's incomplete adjuvant (200 ul) ,,,,,,,, 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0000226,DA.PVG.1AV1-(D4Mgh17-D4Rat56),both,0 days,7,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,12.4,d,0.4914,1.3,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,70200,Freund's incomplete adjuvant (200 ul) ,,,,,,,, 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0000229,DA.PVG.1AV1-(D4Rat63-D4Rat203),both,0 days,37,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,5,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,70201,Freund's incomplete adjuvant (200 ul) ,,,,,,,, 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0000229,DA.PVG.1AV1-(D4Rat63-D4Rat203),both,0 days,37,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,14,d,0.0,0.0,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,70202,Freund's incomplete adjuvant (200 ul) ,,,,,,,, 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0001858,DA/ZtmKini,both,0 days,27,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,96.3,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,70188,Freund's incomplete adjuvant (200 ul) ,,,,,,,, 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0002061,LEW.1AV1/Kini,both,0 days,12,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,70189,Freund's incomplete adjuvant (200 ul) ,,,,,,,, 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0002085,PVG.1AV1/Kini,both,0 days,29,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,70190,Freund's incomplete adjuvant (200 ul) ,,,,,,,, 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0000225,DA.PVG-(D4Rat141-D4Mgh11),both,0 days,30,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,10,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,70191,Freund's incomplete adjuvant (200 ul) ,,,,,,,, 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0001858,DA/ZtmKini,both,0 days,5,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,70192,Freund's incomplete adjuvant (200 ul) ,,,,,,,, 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0003691,DA.PVG.1AV1-(D4Rat63-D4Rat203)/Kiru,both,0 days,11,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,45,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84878,Freund's incomplete adjuvant (200 ul) ,,,,,,,, 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0003692,DA.PVG.1AV1-(D4Rat203-D4Mit22)/Kiru,both,0 days,10,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84879,Freund's incomplete adjuvant (200 ul) ,,,,,,,, 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0002388,DA.PVG.1AV1-(D4Rat231-D4Mit12)/Kini,both,0 days,11,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,13.3,d,0.5427,1.8,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84922,Freund's incomplete adjuvant (200 ul) ,,,,,,,, 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0003370,DA.PVG.1AV1-(D4Rat113-D4Kiru96)/Kiru,both,0 days,8,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,14.4,d,1.7324,4.9,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84923,Freund's incomplete adjuvant (200 ul) ,,,,,,,, 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0003524,DA.PVG.1AV1-(D4Got126-D4Got136),both,0 days,14,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,19,d,1.1759,4.4,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84924,Freund's incomplete adjuvant (200 ul) ,,,,,,,, 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0003371,DA.PVG.1AV1-(D4Rat113-D4Kiru80)/Kiru,both,0 days,11,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,17.2,d,1.6282,5.4,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84925,Freund's incomplete adjuvant (200 ul) ,,,,,,,, 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0003696,DA.PVG.1AV1-(D4Rat113-D4Rat62)/Kiru,both,0 days,18,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,14.8,d,0.7542,3.2,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84926,Freund's incomplete adjuvant (200 ul) ,,,,,,,, 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0003687,PVG.1AV1.DA-(D4Mgh17-D4Rat84)/Kiru,both,0 days,16,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,68.8,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84872,Freund's incomplete adjuvant (200 ul) ,,,,,,,, 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0003683,DA.LEW.1AV1-(D4Mgh17-D4Mgh21)/Kiru,both,0 days,14,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84873,Freund's incomplete adjuvant (200 ul) ,,,,,,,, 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0000227,DA.PVG.1AV1-(D4Rat155-D4Rat84),both,0 days,7,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84874,Freund's incomplete adjuvant (200 ul) ,,,,,,,, 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0003688,DA.PVG.1AV1-(D4Rat155-D4Rat113)/Kiru,both,0 days,9,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84875,Freund's incomplete adjuvant (200 ul) ,,,,,,,, 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0003689,DA.PVG.1AV1-(D4Rat63-D4Rat84)/Kiru,both,0 days,9,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,22,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84876,Freund's incomplete adjuvant (200 ul) ,,,,,,,, 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0003690,DA.PVG.1AV1-(D4Rat203-D4Got130)/Kiru,both,0 days,11,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84877,Freund's incomplete adjuvant (200 ul) ,,,,,,,, 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0003693,DA.PVG.1AV1-(D4Mit22-D4Rat84)/Kiru,both,0 days,12,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84880,Freund's incomplete adjuvant (200 ul) ,,,,,,,, 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0003694,DA.PVG.1AV1-(D4Got126-D4Rat203)/Kiru,both,0 days,7,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,43,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84881,Freund's incomplete adjuvant (200 ul) ,,,,,,,, 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0003689,DA.PVG.1AV1-(D4Rat63-D4Rat84)/Kiru,both,0 days,9,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,17,d,0.9333,2.8,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84900,Freund's incomplete adjuvant (200 ul) ,,,,,,,, 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0003684,LEW.1AV1.DA-(D4Mgh17-D4Rat203)/Kiru,both,0 days,13,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,16,d,0.0,0.0,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84903,Freund's incomplete adjuvant (200 ul) ,,,,,,,, 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0003687,PVG.1AV1.DA-(D4Mgh17-D4Rat84)/Kiru,both,0 days,16,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,20.2,d,2.975,11.9,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84910,Freund's incomplete adjuvant (200 ul) ,,,,,,,, 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0003688,DA.PVG.1AV1-(D4Rat155-D4Rat113)/Kiru,both,0 days,9,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,14.4,d,0.7333,2.2,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84915,Freund's incomplete adjuvant (200 ul) ,,,,,,,, 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0003690,DA.PVG.1AV1-(D4Rat203-D4Got130)/Kiru,both,0 days,11,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,14.9,d,1.0251,3.4,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84916,Freund's incomplete adjuvant (200 ul) ,,,,,,,, 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0003691,DA.PVG.1AV1-(D4Rat63-D4Rat203)/Kiru,both,0 days,11,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,14,d,0.4221,1.4,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84917,Freund's incomplete adjuvant (200 ul) ,,,,,,,, 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0003692,DA.PVG.1AV1-(D4Rat203-D4Mit22)/Kiru,both,0 days,10,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,12.6,d,0.3162,1.0,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84918,Freund's incomplete adjuvant (200 ul) ,,,,,,,, 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0003693,DA.PVG.1AV1-(D4Mit22-D4Rat84)/Kiru,both,0 days,12,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,13,d,0.3753,1.3,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84919,Freund's incomplete adjuvant (200 ul) ,,,,,,,, 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0003694,DA.PVG.1AV1-(D4Got126-D4Rat203)/Kiru,both,0 days,7,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,12.7,d,0.4536,1.2,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84920,Freund's incomplete adjuvant (200 ul) ,,,,,,,, 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0003695,DA.PVG.1AV1-(D4Rat62-D4Got136)/Kiru,both,0 days,12,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,15.4,d,0.664,2.3,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84921,Freund's incomplete adjuvant (200 ul) ,,,,,,,, 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0003695,DA.PVG.1AV1-(D4Rat62-D4Got136)/Kiru,both,0 days,12,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,75,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84882,Freund's incomplete adjuvant (200 ul) ,,,,,,,, 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0002388,DA.PVG.1AV1-(D4Rat231-D4Mit12)/Kini,both,0 days,11,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84883,Freund's incomplete adjuvant (200 ul) ,,,,,,,, 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0003370,DA.PVG.1AV1-(D4Rat113-D4Kiru96)/Kiru,both,0 days,8,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84884,Freund's incomplete adjuvant (200 ul) ,,,,,,,, 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0003524,DA.PVG.1AV1-(D4Got126-D4Got136),both,0 days,14,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,64,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84886,Freund's incomplete adjuvant (200 ul) ,,,,,,,, 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0003371,DA.PVG.1AV1-(D4Rat113-D4Kiru80)/Kiru,both,0 days,11,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,55,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84889,Freund's incomplete adjuvant (200 ul) ,,,,,,,, 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0003696,DA.PVG.1AV1-(D4Rat113-D4Rat62)/Kiru,both,0 days,18,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,89,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84892,Freund's incomplete adjuvant (200 ul) ,,,,,,,, 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0001858,DA/ZtmKini,male,0 days,24,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84465,Freund's incomplete adjuvant (200 ul) ,,,,,,,, 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0001858,DA/ZtmKini,female,0 days,24,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,91.7,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84466,Freund's incomplete adjuvant (200 ul) ,,,,,,,, 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0001858,DA/ZtmKini,male,0 days,24,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,14.6,d,1.388,6.8,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84467,Freund's incomplete adjuvant (200 ul) ,,,,,,,, 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0001858,DA/ZtmKini,female,0 days,24,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,14.6,d,0.6328,3.1,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84468,Freund's incomplete adjuvant (200 ul) ,,,,,,,, 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0001858,DA/ZtmKini,both,0 days,15,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,93,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84469,Freund's incomplete adjuvant (200 ul) ,,,,,,,, 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0001858,DA/ZtmKini,both,0 days,6,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84470,Freund's incomplete adjuvant (200 ul) ,,,,,,,, 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0001858,DA/ZtmKini,both,0 days,15,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,14.9,d,1.5234,5.9,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84471,Freund's incomplete adjuvant (200 ul) ,,,,,,,, 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0001858,DA/ZtmKini,both,0 days,6,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,16.3,d,0.939,2.3,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,84472,Freund's incomplete adjuvant (200 ul) ,,,,,,,, 1158,"Cannon GW, et al., J Rheumatol 1993 Jan;20(1):7-11",joint integrity trait,,RS:0000239,DA/Bkl,male,105 days to 77 days,10,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,50,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (0.1 ml) ,69551,Freund's incomplete adjuvant (0.1 ml) ,,,,,,,, 1158,"Cannon GW, et al., J Rheumatol 1993 Jan;20(1):7-11",joint integrity trait,,RS:0000239,DA/Bkl,male,105 days to 77 days,12,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,83.3,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (0.1 ml) ,69552,Freund's incomplete adjuvant (0.1 ml) ,,,,,,,, 1158,"Cannon GW, et al., J Rheumatol 1993 Jan;20(1):7-11",joint integrity trait,,RS:0000239,DA/Bkl,male,105 days to 70 days,12,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,15.8,d,3.3,11.4315,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (0.1 ml) ,69553,Freund's incomplete adjuvant (0.1 ml) ,,,,,,,, 1158,"Cannon GW, et al., J Rheumatol 1993 Jan;20(1):7-11",joint integrity trait,,RS:0000239,DA/Bkl,male,105 days to 70 days,10,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,14.4,d,1.3,4.111,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (0.1 ml) ,69554,Freund's incomplete adjuvant (0.1 ml) ,,,,,,,, 1158,"Cannon GW, et al., J Rheumatol 1993 Jan;20(1):7-11",joint integrity trait,,RS:0000531,LEW/SsNHsd,not specified,105 days to 77 days,6,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (0.1 ml) ,97068,Freund's incomplete adjuvant (0.1 ml) ,,,,,,,, 1158,"Cannon GW, et al., J Rheumatol 1993 Jan;20(1):7-11",joint integrity trait,,RS:0000531,LEW/SsNHsd,not specified,105 days to 77 days,6,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,0.9% sodium chloride solution (0.1 ml) ,97069,0.9% sodium chloride solution (0.1 ml) ,,,,,,,, 1158,"Cannon GW, et al., J Rheumatol 1993 Jan;20(1):7-11",joint integrity trait,,RS:0000239,DA/Bkl,male,105 days to 77 days,10,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,0.9% sodium chloride solution (0.1 ml) ,97070,0.9% sodium chloride solution (0.1 ml) ,,,,,,,, 1158,"Cannon GW, et al., J Rheumatol 1993 Jan;20(1):7-11",joint integrity trait,,RS:0000239,DA/Bkl,male,105 days to 77 days,12,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,0.9% sodium chloride solution (0.1 ml) ,97071,0.9% sodium chloride solution (0.1 ml) ,,,,,,,, 1278,"Roth MP, et al., J Immunol 1999 Feb 15;162(4):1917-22.",central nervous system integrity trait,,RS:0000113,BN,not specified,122 days to 70 days,9,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,central nervous system myelin (5 mg/ml) and Freund's complete adjuvant (50 %) ,69967,central nervous system myelin (5 mg/ml) ,Freund's complete adjuvant (50 %) ,,,,,,, 1278,"Roth MP, et al., J Immunol 1999 Feb 15;162(4):1917-22.",central nervous system integrity trait,,RS:0000121,LEW,not specified,122 days to 70 days,9,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,central nervous system myelin (5 mg/ml) and Freund's complete adjuvant (50 %) ,69968,central nervous system myelin (5 mg/ml) ,Freund's complete adjuvant (50 %) ,,,,,,, 1279,"Dahlman I, et al., Hum Mol Genet 1999 Nov;8(12):2183-90.",central nervous system integrity trait,,RS:0000242,DA/Ztm,not specified,145 days to 70 days,36,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,72,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,myelin oligodendrocyte glycoprotein (0.25 mg/ml) and Freund's incomplete adjuvant (50 %) ,69969,myelin oligodendrocyte glycoprotein (0.25 mg/ml) ,Freund's incomplete adjuvant (50 %) ,,,,,,, 1279,"Dahlman I, et al., Hum Mol Genet 1999 Nov;8(12):2183-90.",central nervous system integrity trait,,RS:0000032,ACI/SegHsd,not specified,145 days to 70 days,21,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,5,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,myelin oligodendrocyte glycoprotein (0.25 mg/ml) and Freund's incomplete adjuvant (50 %) ,69970,myelin oligodendrocyte glycoprotein (0.25 mg/ml) ,Freund's incomplete adjuvant (50 %) ,,,,,,, 1282,"Olofsson P, et al., Arthritis Rheum 2002 Jan;46(1):259-68.",joint integrity trait,,RS:0001675,DA/ZtmRhd,both,234 days to 56 days,10,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,1.296E7,,,,,pristane (150 ul) ,70128,pristane (150 ul) ,,,,,,,, 1282,"Olofsson P, et al., Arthritis Rheum 2002 Jan;46(1):259-68.",joint integrity trait,,RS:0000497,LEW.1F,both,234 days to 56 days,11,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,1.296E7,,,,,pristane (150 ul) ,70129,pristane (150 ul) ,,,,,,,, 1282,"Olofsson P, et al., Arthritis Rheum 2002 Jan;46(1):259-68.",joint integrity trait,,RS:0000202,E3,both,234 days to 56 days,10,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,1.296E7,,,,,pristane (150 ul) ,70130,pristane (150 ul) ,,,,,,,, 1282,"Olofsson P, et al., Arthritis Rheum 2002 Jan;46(1):259-68.",joint integrity trait,,RS:0001675,DA/ZtmRhd,both,234 days to 56 days,10,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,14,d,0.3162,1.0,MMO:0000163,in vivo visual assessment,,1.296E7,,,,,pristane (150 ul) ,70131,pristane (150 ul) ,,,,,,,, 1282,"Olofsson P, et al., Arthritis Rheum 2002 Jan;46(1):259-68.",joint integrity trait,,RS:0000202,E3,both,234 days to 56 days,10,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,0,d,,,MMO:0000163,in vivo visual assessment,,1.296E7,,,,,pristane (150 ul) ,70132,pristane (150 ul) ,,,,,,,, 1282,"Olofsson P, et al., Arthritis Rheum 2002 Jan;46(1):259-68.",joint integrity trait,,RS:0000497,LEW.1F,both,234 days to 56 days,11,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,17,d,0.9045,3.0,MMO:0000163,in vivo visual assessment,,1.296E7,,,,,pristane (150 ul) ,70133,pristane (150 ul) ,,,,,,,, 1282,"Olofsson P, et al., Arthritis Rheum 2002 Jan;46(1):259-68.",joint integrity trait,,RS:0001675,DA/ZtmRhd,both,234 days to 56 days,10,,CMO:0001491,subjects with ankylosis to total subjects with arthritis ratio,,,,75,%,,,MMO:0000163,in vivo visual assessment,tail,1.296E7,,,,,pristane (150 ul) ,70134,pristane (150 ul) ,,,,,,,, 1282,"Olofsson P, et al., Arthritis Rheum 2002 Jan;46(1):259-68.",joint integrity trait,,RS:0000497,LEW.1F,both,234 days to 56 days,11,,CMO:0001491,subjects with ankylosis to total subjects with arthritis ratio,,,,0,%,,,MMO:0000163,in vivo visual assessment,tail,1.296E7,,,,,pristane (150 ul) ,70135,pristane (150 ul) ,,,,,,,, 1282,"Olofsson P, et al., Arthritis Rheum 2002 Jan;46(1):259-68.",joint integrity trait,,RS:0000202,E3,both,234 days to 56 days,10,,CMO:0001491,subjects with ankylosis to total subjects with arthritis ratio,,,,0,%,,,MMO:0000163,in vivo visual assessment,tail,1.296E7,,,,,pristane (150 ul) ,70136,pristane (150 ul) ,,,,,,,, 1282,"Olofsson P, et al., Arthritis Rheum 2002 Jan;46(1):259-68.",joint integrity trait,,RS:0001675,DA/ZtmRhd,both,234 days to 56 days,10,,CMO:0001460,arthritic paw count,,,,3.7,,0.1581,0.5,MMO:0000163,in vivo visual assessment,tail,1.296E7,,,,,pristane (150 ul) ,70137,pristane (150 ul) ,,,,,,,, 1282,"Olofsson P, et al., Arthritis Rheum 2002 Jan;46(1):259-68.",joint integrity trait,,RS:0000497,LEW.1F,both,234 days to 56 days,11,,CMO:0001460,arthritic paw count,,,,3.4,,0.2111,0.7,MMO:0000163,in vivo visual assessment,tail,1.296E7,,,,,pristane (150 ul) ,70138,pristane (150 ul) ,,,,,,,, 1282,"Olofsson P, et al., Arthritis Rheum 2002 Jan;46(1):259-68.",joint integrity trait,,RS:0000202,E3,both,234 days to 56 days,10,,CMO:0001460,arthritic paw count,,,,0,,,,MMO:0000163,in vivo visual assessment,tail,1.296E7,,,,,pristane (150 ul) ,70139,pristane (150 ul) ,,,,,,,, 1161,"Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72.",joint integrity trait,,RS:0000242,DA/Ztm,female,0 days,8,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (860 mg/ml) ,69624,squalene (860 mg/ml) ,,,,,,,, 1161,"Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72.",joint integrity trait,,RS:0000242,DA/Ztm,male,0 days,6,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (860 mg/ml) ,69625,squalene (860 mg/ml) ,,,,,,,, 1161,"Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72.",joint integrity trait,,RS:0000494,LEW.1AV1.DA-(D10Rat92-D10Rat135)/Ubc,female,0 days,15,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,73,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (860 mg/ml) ,69626,squalene (860 mg/ml) ,,,,,,,, 1161,"Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72.",joint integrity trait,,RS:0000494,LEW.1AV1.DA-(D10Rat92-D10Rat135)/Ubc,male,0 days,13,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,85,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (860 mg/ml) ,69627,squalene (860 mg/ml) ,,,,,,,, 1161,"Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72.",joint integrity trait,,RS:0000491,LEW.1AV1,female,0 days,14,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,14,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (860 mg/ml) ,69628,squalene (860 mg/ml) ,,,,,,,, 1161,"Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72.",joint integrity trait,,RS:0000491,LEW.1AV1,male,0 days,9,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,11,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (860 mg/ml) ,69629,squalene (860 mg/ml) ,,,,,,,, 1161,"Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72.",joint integrity trait,,RS:0000242,DA/Ztm,female,0 days,8,,CMO:0001491,subjects with ankylosis to total subjects with arthritis ratio,,,,38,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (860 mg/ml) ,69630,squalene (860 mg/ml) ,,,,,,,, 1161,"Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72.",joint integrity trait,,RS:0000242,DA/Ztm,male,0 days,6,,CMO:0001491,subjects with ankylosis to total subjects with arthritis ratio,,,,50,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (860 mg/ml) ,69631,squalene (860 mg/ml) ,,,,,,,, 1161,"Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72.",joint integrity trait,,RS:0000494,LEW.1AV1.DA-(D10Rat92-D10Rat135)/Ubc,female,0 days,11,,CMO:0001491,subjects with ankylosis to total subjects with arthritis ratio,,,,18,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (860 mg/ml) ,69632,squalene (860 mg/ml) ,,,,,,,, 1161,"Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72.",joint integrity trait,,RS:0000494,LEW.1AV1.DA-(D10Rat92-D10Rat135)/Ubc,male,0 days,11,,CMO:0001491,subjects with ankylosis to total subjects with arthritis ratio,,,,36,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (860 mg/ml) ,69633,squalene (860 mg/ml) ,,,,,,,, 1161,"Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72.",joint integrity trait,,RS:0000491,LEW.1AV1,female,0 days,2,,CMO:0001491,subjects with ankylosis to total subjects with arthritis ratio,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (860 mg/ml) ,69634,squalene (860 mg/ml) ,,,,,,,, 1161,"Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72.",joint integrity trait,,RS:0000491,LEW.1AV1,male,0 days,1,,CMO:0001491,subjects with ankylosis to total subjects with arthritis ratio,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (860 mg/ml) ,69635,squalene (860 mg/ml) ,,,,,,,, 1161,"Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72.",joint integrity trait,,RS:0000242,DA/Ztm,female,0 days,8,,CMO:0001450,post-insult time to onset of experimental arthritis,,,median,14,d,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (860 mg/ml) ,69636,squalene (860 mg/ml) ,,,,,,,, 1161,"Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72.",joint integrity trait,,RS:0000242,DA/Ztm,male,0 days,6,,CMO:0001450,post-insult time to onset of experimental arthritis,,,median,14,d,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (860 mg/ml) ,69637,squalene (860 mg/ml) ,,,,,,,, 1161,"Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72.",joint integrity trait,,RS:0000494,LEW.1AV1.DA-(D10Rat92-D10Rat135)/Ubc,female,0 days,11,,CMO:0001450,post-insult time to onset of experimental arthritis,,,median,18,d,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (860 mg/ml) ,69638,squalene (860 mg/ml) ,,,,,,,, 1161,"Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72.",joint integrity trait,,RS:0000494,LEW.1AV1.DA-(D10Rat92-D10Rat135)/Ubc,male,0 days,11,,CMO:0001450,post-insult time to onset of experimental arthritis,,,median,18,d,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (860 mg/ml) ,69639,squalene (860 mg/ml) ,,,,,,,, 1161,"Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72.",joint integrity trait,,RS:0000491,LEW.1AV1,female,0 days,2,,CMO:0001450,post-insult time to onset of experimental arthritis,,,median,18,d,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (860 mg/ml) ,69640,squalene (860 mg/ml) ,,,,,,,, 1161,"Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72.",joint integrity trait,,RS:0000491,LEW.1AV1,male,0 days,1,,CMO:0001450,post-insult time to onset of experimental arthritis,,,median,22,d,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (860 mg/ml) ,69641,squalene (860 mg/ml) ,,,,,,,, 1161,"Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72.",joint integrity trait,,RS:0000495,LEW.1AV1.DA-(D10Rat92-D10Wox17)/Ubc,female,0 days,17,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,29,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (860 mg/ml) ,69642,squalene (860 mg/ml) ,,,,,,,, 1161,"Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72.",joint integrity trait,,RS:0000495,LEW.1AV1.DA-(D10Rat92-D10Wox17)/Ubc,male,0 days,6,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,33,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (860 mg/ml) ,69643,squalene (860 mg/ml) ,,,,,,,, 1161,"Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72.",joint integrity trait,,RS:0000496,LEW.1AV1.DA-(D10Wox17-D10Rat135)/Ubc,female,0 days,13,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,77,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (860 mg/ml) ,69644,squalene (860 mg/ml) ,,,,,,,, 1161,"Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72.",joint integrity trait,,RS:0000496,LEW.1AV1.DA-(D10Wox17-D10Rat135)/Ubc,male,0 days,17,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,71,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (860 mg/ml) ,69645,squalene (860 mg/ml) ,,,,,,,, 1161,"Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72.",joint integrity trait,,RS:0000492,LEW.1AV1.DA-(D10Got154-D10Rat135)/Ubc,female,0 days,26,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,69,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (860 mg/ml) ,69646,squalene (860 mg/ml) ,,,,,,,, 1161,"Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72.",joint integrity trait,,RS:0000492,LEW.1AV1.DA-(D10Got154-D10Rat135)/Ubc,male,0 days,28,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,50,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (860 mg/ml) ,69647,squalene (860 mg/ml) ,,,,,,,, 1161,"Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72.",joint integrity trait,,RS:0000495,LEW.1AV1.DA-(D10Rat92-D10Wox17)/Ubc,female,0 days,17,,CMO:0001450,post-insult time to onset of experimental arthritis,,,median,24,d,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (860 mg/ml) ,69648,squalene (860 mg/ml) ,,,,,,,, 1161,"Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72.",joint integrity trait,,RS:0000495,LEW.1AV1.DA-(D10Rat92-D10Wox17)/Ubc,male,0 days,6,,CMO:0001450,post-insult time to onset of experimental arthritis,,,median,22,d,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (860 mg/ml) ,69649,squalene (860 mg/ml) ,,,,,,,, 1161,"Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72.",joint integrity trait,,RS:0000496,LEW.1AV1.DA-(D10Wox17-D10Rat135)/Ubc,female,0 days,13,,CMO:0001450,post-insult time to onset of experimental arthritis,,,median,22,d,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (860 mg/ml) ,69650,squalene (860 mg/ml) ,,,,,,,, 1161,"Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72.",joint integrity trait,,RS:0000496,LEW.1AV1.DA-(D10Wox17-D10Rat135)/Ubc,male,0 days,17,,CMO:0001450,post-insult time to onset of experimental arthritis,,,median,24,d,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (860 mg/ml) ,69651,squalene (860 mg/ml) ,,,,,,,, 1161,"Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72.",joint integrity trait,,RS:0000492,LEW.1AV1.DA-(D10Got154-D10Rat135)/Ubc,female,0 days,26,,CMO:0001450,post-insult time to onset of experimental arthritis,,,median,22,d,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (860 mg/ml) ,69652,squalene (860 mg/ml) ,,,,,,,, 1161,"Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72.",joint integrity trait,,RS:0000492,LEW.1AV1.DA-(D10Got154-D10Rat135)/Ubc,male,0 days,28,,CMO:0001450,post-insult time to onset of experimental arthritis,,,median,24,d,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (860 mg/ml) ,69653,squalene (860 mg/ml) ,,,,,,,, 1160,"Vingsbo-Lundberg C, et al., Nat Genet 1998 Dec;20(4):401-4",joint integrity trait,,RS:0001675,DA/ZtmRhd,both,0 days,30,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,93,%,,,MMO:0000163,in vivo visual assessment,,4838400.0,,,,,pristane (150 ul) (for 56 days),69591,pristane (150 ul) (for 56 days),,,,,,,, 1160,"Vingsbo-Lundberg C, et al., Nat Genet 1998 Dec;20(4):401-4",joint integrity trait,,RS:0000208,E3/ZtmRhd,both,0 days,25,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,4838400.0,,,,,pristane (150 ul) (for 56 days),69592,pristane (150 ul) (for 56 days),,,,,,,, 1160,"Vingsbo-Lundberg C, et al., Nat Genet 1998 Dec;20(4):401-4",joint integrity trait,,RS:0001675,DA/ZtmRhd,both,0 days,30,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,14,d,0.3651,2.0,MMO:0000163,in vivo visual assessment,,4838400.0,,,,,pristane (150 ul) (for 56 days),69593,pristane (150 ul) (for 56 days),,,,,,,, 1160,"Vingsbo-Lundberg C, et al., Nat Genet 1998 Dec;20(4):401-4",joint integrity trait,,RS:0001675,DA/ZtmRhd,both,0 days,30,,CMO:0001456,percentage of study population developing chronic experimental arthritis during a period of time,,,,87,%,,,MMO:0000163,in vivo visual assessment,,1.0368E7,,,,,pristane (150 ul) (for 120 days),69595,pristane (150 ul) (for 120 days),,,,,,,, 1160,"Vingsbo-Lundberg C, et al., Nat Genet 1998 Dec;20(4):401-4",joint integrity trait,,RS:0000208,E3/ZtmRhd,both,0 days,25,,CMO:0001456,percentage of study population developing chronic experimental arthritis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,1.0368E7,,,,,pristane (150 ul) (for 120 days),69966,pristane (150 ul) (for 120 days),,,,,,,, 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000242,DA/Ztm,both,200 days to 120 days,17,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69716,pristane (150 ul) ,,,,,,,, 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000644,PVG.1AV1,both,200 days to 120 days,18,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,33,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69717,pristane (150 ul) ,,,,,,,, 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000227,DA.PVG.1AV1-(D4Rat155-D4Rat84),both,200 days to 120 days,16,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,69,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69718,pristane (150 ul) ,,,,,,,, 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000228,DA.PVG.1AV1-(D4Rat155-Spr),both,200 days to 120 days,24,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69719,pristane (150 ul) ,,,,,,,, 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000242,DA/Ztm,both,200 days to 120 days,9,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (200 ul) ,69720,squalene (200 ul) ,,,,,,,, 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000229,DA.PVG.1AV1-(D4Rat63-D4Rat203),both,200 days to 120 days,10,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (200 ul) ,69721,squalene (200 ul) ,,,,,,,, 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000242,DA/Ztm,both,200 days to 120 days,10,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) ,69722,type II collagen (500 ug) ,Freund's incomplete adjuvant (100 ul) ,,,,,,, 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000229,DA.PVG.1AV1-(D4Rat63-D4Rat203),both,200 days to 120 days,10,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) ,69723,type II collagen (500 ug) ,Freund's incomplete adjuvant (100 ul) ,,,,,,, 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000242,DA/Ztm,both,200 days to 120 days,10,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69724,pristane (150 ul) ,,,,,,,, 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000229,DA.PVG.1AV1-(D4Rat63-D4Rat203),both,200 days to 120 days,10,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,90,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69725,pristane (150 ul) ,,,,,,,, 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000242,DA/Ztm,both,200 days to 120 days,15,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,13,d,0.4,1.5492,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (200 ul) ,69773,squalene (200 ul) ,,,,,,,, 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000227,DA.PVG.1AV1-(D4Rat155-D4Rat84),both,200 days to 120 days,11,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,16,d,0.4,1.3266,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (200 ul) ,69774,squalene (200 ul) ,,,,,,,, 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000242,DA/Ztm,both,200 days to 120 days,16,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,14.9,d,0.5,2.0,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's complete adjuvant (100 ul) ,69775,Freund's complete adjuvant (100 ul) ,,,,,,,, 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000227,DA.PVG.1AV1-(D4Rat155-D4Rat84),both,200 days to 120 days,14,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,13.6,d,0.4,1.4967,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's complete adjuvant (100 ul) ,69776,Freund's complete adjuvant (100 ul) ,,,,,,,, 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000242,DA/Ztm,both,200 days to 120 days,12,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,14.5,d,0.5,1.7321,MMO:0000163,in vivo visual assessment,,0.0,,,,,type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) ,69777,type II collagen (500 ug) ,Freund's incomplete adjuvant (100 ul) ,,,,,,, 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000242,DA/Ztm,both,200 days to 120 days,15,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (200 ul) ,69703,squalene (200 ul) ,,,,,,,, 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000644,PVG.1AV1,both,200 days to 120 days,10,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (200 ul) ,69704,squalene (200 ul) ,,,,,,,, 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000227,DA.PVG.1AV1-(D4Rat155-D4Rat84),both,200 days to 120 days,11,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,73,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (200 ul) ,69705,squalene (200 ul) ,,,,,,,, 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000242,DA/Ztm,both,200 days to 120 days,16,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,88,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's complete adjuvant (100 ul) ,69706,Freund's complete adjuvant (100 ul) ,,,,,,,, 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000644,PVG.1AV1,both,200 days to 120 days,15,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's complete adjuvant (100 ul) ,69707,Freund's complete adjuvant (100 ul) ,,,,,,,, 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000227,DA.PVG.1AV1-(D4Rat155-D4Rat84),both,200 days to 120 days,14,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,36,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's complete adjuvant (100 ul) ,69708,Freund's complete adjuvant (100 ul) ,,,,,,,, 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000242,DA/Ztm,both,200 days to 120 days,12,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) ,69709,type II collagen (500 ug) ,Freund's incomplete adjuvant (100 ul) ,,,,,,, 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000644,PVG.1AV1,both,200 days to 120 days,15,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,33,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) ,69710,type II collagen (500 ug) ,Freund's incomplete adjuvant (100 ul) ,,,,,,, 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000227,DA.PVG.1AV1-(D4Rat155-D4Rat84),both,200 days to 120 days,14,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,71,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) ,69711,type II collagen (500 ug) ,Freund's incomplete adjuvant (100 ul) ,,,,,,, 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000228,DA.PVG.1AV1-(D4Rat155-Spr),both,200 days to 120 days,14,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) ,69712,type II collagen (500 ug) ,Freund's incomplete adjuvant (100 ul) ,,,,,,, 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000226,DA.PVG.1AV1-(D4Mgh17-D4Rat56),both,200 days to 120 days,11,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) ,69713,type II collagen (500 ug) ,Freund's incomplete adjuvant (100 ul) ,,,,,,, 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000242,DA/Ztm,male,200 days to 120 days,9,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) ,69714,type II collagen (500 ug) ,Freund's incomplete adjuvant (100 ul) ,,,,,,, 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000226,DA.PVG.1AV1-(D4Mgh17-D4Rat56),male,200 days to 120 days,13,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) ,69715,type II collagen (500 ug) ,Freund's incomplete adjuvant (100 ul) ,,,,,,, 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000644,PVG.1AV1,both,200 days to 120 days,15,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,14.6,d,0.4,1.5492,MMO:0000163,in vivo visual assessment,,0.0,,,,,type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) ,69778,type II collagen (500 ug) ,Freund's incomplete adjuvant (100 ul) ,,,,,,, 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000227,DA.PVG.1AV1-(D4Rat155-D4Rat84),both,200 days to 120 days,14,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,17.6,d,0.8,2.9933,MMO:0000163,in vivo visual assessment,,0.0,,,,,type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) ,69779,type II collagen (500 ug) ,Freund's incomplete adjuvant (100 ul) ,,,,,,, 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000228,DA.PVG.1AV1-(D4Rat155-Spr),both,200 days to 120 days,14,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,14.3,d,0.3,1.1225,MMO:0000163,in vivo visual assessment,,0.0,,,,,type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) ,69780,type II collagen (500 ug) ,Freund's incomplete adjuvant (100 ul) ,,,,,,, 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000226,DA.PVG.1AV1-(D4Mgh17-D4Rat56),both,200 days to 120 days,11,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,15.4,d,0.5,1.6583,MMO:0000163,in vivo visual assessment,,0.0,,,,,type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) ,69781,type II collagen (500 ug) ,Freund's incomplete adjuvant (100 ul) ,,,,,,, 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000226,DA.PVG.1AV1-(D4Mgh17-D4Rat56),male,200 days to 120 days,13,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,15.5,d,0.2,0.7211,MMO:0000163,in vivo visual assessment,,0.0,,,,,type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) ,69783,type II collagen (500 ug) ,Freund's incomplete adjuvant (100 ul) ,,,,,,, 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000242,DA/Ztm,both,200 days to 120 days,17,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,12.1,d,0.3,1.2369,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69784,pristane (150 ul) ,,,,,,,, 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000644,PVG.1AV1,both,200 days to 120 days,18,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,38,d,1.2,5.0912,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69785,pristane (150 ul) ,,,,,,,, 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000227,DA.PVG.1AV1-(D4Rat155-D4Rat84),both,200 days to 120 days,16,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,13.1,d,1.1,4.4,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69786,pristane (150 ul) ,,,,,,,, 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000228,DA.PVG.1AV1-(D4Rat155-Spr),both,200 days to 120 days,24,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,12.5,d,0.5,2.4495,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69787,pristane (150 ul) ,,,,,,,, 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000242,DA/Ztm,both,200 days to 120 days,9,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,14,d,0.7,2.1,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (200 ul) ,69788,squalene (200 ul) ,,,,,,,, 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000229,DA.PVG.1AV1-(D4Rat63-D4Rat203),both,200 days to 120 days,10,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,16.9,d,0.6,1.8974,MMO:0000163,in vivo visual assessment,,0.0,,,,,squalene (200 ul) ,69789,squalene (200 ul) ,,,,,,,, 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000242,DA/Ztm,both,200 days to 120 days,10,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,14.2,d,0.4,1.2649,MMO:0000163,in vivo visual assessment,,0.0,,,,,type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) ,69790,type II collagen (500 ug) ,Freund's incomplete adjuvant (100 ul) ,,,,,,, 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000229,DA.PVG.1AV1-(D4Rat63-D4Rat203),both,200 days to 120 days,10,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,16.4,d,0.8,2.5298,MMO:0000163,in vivo visual assessment,,0.0,,,,,type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) ,69791,type II collagen (500 ug) ,Freund's incomplete adjuvant (100 ul) ,,,,,,, 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000242,DA/Ztm,both,200 days to 120 days,10,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,14.2,d,1.1,3.4785,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69792,pristane (150 ul) ,,,,,,,, 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000229,DA.PVG.1AV1-(D4Rat63-D4Rat203),both,200 days to 120 days,10,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,15.5,d,0.8,2.5298,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69793,pristane (150 ul) ,,,,,,,, 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000242,DA/Ztm,male,200 days to 120 days,9,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,15.2,d,0.2,0.6,MMO:0000163,in vivo visual assessment,,0.0,,,,,type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) ,69782,type II collagen (500 ug) ,Freund's incomplete adjuvant (100 ul) ,,,,,,, 1298,"Nordquist N, et al., J Autoimmun 2000 Dec;15(4):425-32.",joint integrity trait,,RS:0000384,DXE3/Ztm,both,0 days,29,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,3,%,,,MMO:0000163,in vivo visual assessment,,9504000.0,,,,,pristane (150 ul) (for 110 days),70142,pristane (150 ul) (for 110 days),,,,,,,, 1298,"Nordquist N, et al., J Autoimmun 2000 Dec;15(4):425-32.",joint integrity trait,,RS:0000384,DXE3/Ztm,both,0 days,1,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,43,d,,,MMO:0000163,in vivo visual assessment,,9504000.0,,,,,pristane (150 ul) (for 110 days),70145,pristane (150 ul) (for 110 days),,,,,,,, 1299,"Joe B, et al., Immunogenetics 2000 Sep;51(11):930-44.",joint integrity trait,,RS:0000239,DA/Bkl,male,126 days to 63 days,15,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,3024000.0,,,,,type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) ,70146,type II collagen (2 mg/kg) ,Freund's incomplete adjuvant (50 %) ,,,,,,, 1299,"Joe B, et al., Immunogenetics 2000 Sep;51(11):930-44.",joint integrity trait,,RS:0000239,DA/Bkl,female,126 days to 63 days,14,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,3024000.0,,,,,type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) ,70147,type II collagen (2 mg/kg) ,Freund's incomplete adjuvant (50 %) ,,,,,,, 1299,"Joe B, et al., Immunogenetics 2000 Sep;51(11):930-44.",joint integrity trait,,RS:0000363,F344/NHsd,male,126 days to 63 days,10,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,20,%,,,MMO:0000163,in vivo visual assessment,,3024000.0,,,,,type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) ,70148,type II collagen (2 mg/kg) ,Freund's incomplete adjuvant (50 %) ,,,,,,, 1299,"Joe B, et al., Immunogenetics 2000 Sep;51(11):930-44.",joint integrity trait,,RS:0000363,F344/NHsd,female,126 days to 63 days,10,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,30,%,,,MMO:0000163,in vivo visual assessment,,3024000.0,,,,,type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) ,70149,type II collagen (2 mg/kg) ,Freund's incomplete adjuvant (50 %) ,,,,,,, 1299,"Joe B, et al., Immunogenetics 2000 Sep;51(11):930-44.",joint integrity trait,,RS:0000209,DA.F344-(D10Arb20-D10Arb22)/Arb,male,126 days to 63 days,10,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,3024000.0,,,,,type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) ,70152,type II collagen (2 mg/kg) ,Freund's incomplete adjuvant (50 %) ,,,,,,, 1299,"Joe B, et al., Immunogenetics 2000 Sep;51(11):930-44.",joint integrity trait,,RS:0000209,DA.F344-(D10Arb20-D10Arb22)/Arb,female,126 days to 63 days,10,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,3024000.0,,,,,type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) ,70153,type II collagen (2 mg/kg) ,Freund's incomplete adjuvant (50 %) ,,,,,,, 1299,"Joe B, et al., Immunogenetics 2000 Sep;51(11):930-44.",joint integrity trait,,RS:0001225,DA.F344-(D10Rat204-D10Arb22)/Arb,male,126 days to 63 days,9,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,3024000.0,,,,,type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) ,70154,type II collagen (2 mg/kg) ,Freund's incomplete adjuvant (50 %) ,,,,,,, 1299,"Joe B, et al., Immunogenetics 2000 Sep;51(11):930-44.",joint integrity trait,,RS:0001225,DA.F344-(D10Rat204-D10Arb22)/Arb,female,126 days to 63 days,10,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,3024000.0,,,,,type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) ,70155,type II collagen (2 mg/kg) ,Freund's incomplete adjuvant (50 %) ,,,,,,, 1163,"Lu S, et al., Eur J Hum Genet 2002 Aug;10(8):475-83.",joint integrity trait,,RS:0000497,LEW.1F,male,84 days to 56 days,14,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,86,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69813,pristane (150 ul) ,,,,,,,, 1163,"Lu S, et al., Eur J Hum Genet 2002 Aug;10(8):475-83.",joint integrity trait,,RS:0000497,LEW.1F,female,84 days to 56 days,8,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69814,pristane (150 ul) ,,,,,,,, 1163,"Lu S, et al., Eur J Hum Genet 2002 Aug;10(8):475-83.",joint integrity trait,,RS:0000202,E3,male,84 days to 56 days,5,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69815,pristane (150 ul) ,,,,,,,, 1163,"Lu S, et al., Eur J Hum Genet 2002 Aug;10(8):475-83.",joint integrity trait,,RS:0000202,E3,female,84 days to 56 days,5,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69816,pristane (150 ul) ,,,,,,,, 1163,"Lu S, et al., Eur J Hum Genet 2002 Aug;10(8):475-83.",joint integrity trait,,RS:0000497,LEW.1F,male,84 days to 56 days,14,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,31,d,7.0,26.1916,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69817,pristane (150 ul) ,,,,,,,, 1163,"Lu S, et al., Eur J Hum Genet 2002 Aug;10(8):475-83.",joint integrity trait,,RS:0000497,LEW.1F,female,84 days to 56 days,8,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,18,d,1.0,2.8284,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69818,pristane (150 ul) ,,,,,,,, 1164,"Olofsson P, et al., J Immunol 2003 Jul 1;171(1):407-16.",joint integrity trait,,RS:0001675,DA/ZtmRhd,both,84 days to 56 days,104,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,2419200.0,,,,,pristane (150 ul) ,69838,pristane (150 ul) ,,,,,,,, 1164,"Olofsson P, et al., J Immunol 2003 Jul 1;171(1):407-16.",joint integrity trait,,RS:0000208,E3/ZtmRhd,both,84 days to 56 days,10,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,2419200.0,,,,,pristane (150 ul) ,69839,pristane (150 ul) ,,,,,,,, 1164,"Olofsson P, et al., J Immunol 2003 Jul 1;171(1):407-16.",joint integrity trait,,RS:0001675,DA/ZtmRhd,both,84 days to 56 days,104,,CMO:0001460,arthritic paw count,,,,3.3,,0.1,1.0198,MMO:0000163,in vivo visual assessment,,2419200.0,,,,,pristane (150 ul) ,69840,pristane (150 ul) ,,,,,,,, 1164,"Olofsson P, et al., J Immunol 2003 Jul 1;171(1):407-16.",joint integrity trait,,RS:0000208,E3/ZtmRhd,both,84 days to 56 days,10,,CMO:0001460,arthritic paw count,,,,0,,,,MMO:0000163,in vivo visual assessment,,2419200.0,,,,,pristane (150 ul) ,69841,pristane (150 ul) ,,,,,,,, 1164,"Olofsson P, et al., J Immunol 2003 Jul 1;171(1):407-16.",joint integrity trait,,RS:0001675,DA/ZtmRhd,both,84 days to 56 days,104,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,12,d,0.2,2.0396,MMO:0000163,in vivo visual assessment,,2419200.0,,,,,pristane (150 ul) ,69842,pristane (150 ul) ,,,,,,,, 1241,"Furuya T, et al., Hum Mol Genet 2000 Sep 22;9(15):2241-50",joint integrity trait,,RS:0000073,BBDR/Rhw,male,126 days to 66 days,11,,CMO:0001456,percentage of study population developing chronic experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (50 %) (between 1 and 7 days) and type II collagen (2 mg/kg) (between 1 and 7 days) then Freund's incomplete adjuvant (50 %) (between 1 and 35 days) and type II collagen (100 ug) (between 1 and 35 days),69921,Freund's incomplete adjuvant (50 %) (between 1 and 7 days),type II collagen (2 mg/kg) (between 1 and 7 days),,Freund's incomplete adjuvant (50 %) (between 1 and 35 days),type II collagen (100 ug) (between 1 and 35 days),,,, 1241,"Furuya T, et al., Hum Mol Genet 2000 Sep 22;9(15):2241-50",joint integrity trait,,RS:0000073,BBDR/Rhw,female,126 days to 66 days,13,,CMO:0001456,percentage of study population developing chronic experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (50 %) (between 1 and 7 days) and type II collagen (2 mg/kg) (between 1 and 7 days) then Freund's incomplete adjuvant (50 %) (between 1 and 35 days) and type II collagen (100 ug) (between 1 and 35 days),69922,Freund's incomplete adjuvant (50 %) (between 1 and 7 days),type II collagen (2 mg/kg) (between 1 and 7 days),,Freund's incomplete adjuvant (50 %) (between 1 and 35 days),type II collagen (100 ug) (between 1 and 35 days),,,, 1241,"Furuya T, et al., Hum Mol Genet 2000 Sep 22;9(15):2241-50",joint integrity trait,,RS:0000154,BN/SsN,male,126 days to 66 days,13,,CMO:0001456,percentage of study population developing chronic experimental arthritis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (50 %) (between 1 and 7 days) and type II collagen (2 mg/kg) (between 1 and 7 days) then Freund's incomplete adjuvant (50 %) (between 1 and 35 days) and type II collagen (100 ug) (between 1 and 35 days),69923,Freund's incomplete adjuvant (50 %) (between 1 and 7 days),type II collagen (2 mg/kg) (between 1 and 7 days),,Freund's incomplete adjuvant (50 %) (between 1 and 35 days),type II collagen (100 ug) (between 1 and 35 days),,,, 1241,"Furuya T, et al., Hum Mol Genet 2000 Sep 22;9(15):2241-50",joint integrity trait,,RS:0000154,BN/SsN,female,126 days to 66 days,7,,CMO:0001456,percentage of study population developing chronic experimental arthritis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (50 %) (between 1 and 7 days) and type II collagen (2 mg/kg) (between 1 and 7 days) then Freund's incomplete adjuvant (50 %) (between 1 and 35 days) and type II collagen (100 ug) (between 1 and 35 days),69924,Freund's incomplete adjuvant (50 %) (between 1 and 7 days),type II collagen (2 mg/kg) (between 1 and 7 days),,Freund's incomplete adjuvant (50 %) (between 1 and 35 days),type II collagen (100 ug) (between 1 and 35 days),,,, 2018,"van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28.",trigeminal nerve integrity trait,,RS:0004305,BDIX.BDIV-D6Rat132-D6Mgh3/Zte,male,200 days,39,,CMO:0002016,percentage of study population displaying trigeminal nerve neurilemmomas at a point in time,,SD approximated from 95%CI,,22,%,1.1209,7.0,MMO:0000163,in vivo visual assessment,,0.0,inferred from Kaplan-Meier plot analysis,,,,N-ethyl-N-nitrosourea (80 ug/g) ,98148,N-ethyl-N-nitrosourea (80 ug/g) ,,,,,,,, 2018,"van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28.",trigeminal nerve integrity trait,,RS:0000091,BDIX,female,200 days,52,,CMO:0002016,percentage of study population displaying trigeminal nerve neurilemmomas at a point in time,,SD approximated from 95%CI,,41,%,1.0747,7.75,MMO:0000163,in vivo visual assessment,,0.0,inferred from Kaplan-Meier plot analysis,,,,N-ethyl-N-nitrosourea (80 ug/g) ,98143,N-ethyl-N-nitrosourea (80 ug/g) ,,,,,,,, 2018,"van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28.",trigeminal nerve integrity trait,,RS:0000091,BDIX,both,200 days,109,,CMO:0002016,percentage of study population displaying trigeminal nerve neurilemmomas at a point in time,,SD approximated from 95%CI,,49,%,0.4789,5.0,MMO:0000163,in vivo visual assessment,,0.0,inferred from Kaplan-Meier plot analysis,,,,N-ethyl-N-nitrosourea (80 ug/g) ,98144,N-ethyl-N-nitrosourea (80 ug/g) ,,,,,,,, 2018,"van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28.",trigeminal nerve integrity trait,,RS:0004304,BDIX.BDIV-D6Mit1-D6Mgh2/Zte,male,200 days,51,,CMO:0002016,percentage of study population displaying trigeminal nerve neurilemmomas at a point in time,,SD approximated from 95%CI,,38,%,1.0502,7.5,MMO:0000163,in vivo visual assessment,,0.0,inferred from Kaplan-Meier plot analysis,,,,N-ethyl-N-nitrosourea (80 ug/g) ,98145,N-ethyl-N-nitrosourea (80 ug/g) ,,,,,,,, 2018,"van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28.",trigeminal nerve integrity trait,,RS:0004304,BDIX.BDIV-D6Mit1-D6Mgh2/Zte,female,200 days,49,,CMO:0002016,percentage of study population displaying trigeminal nerve neurilemmomas at a point in time,,SD approximated from 95%CI,,10,%,0.4643,3.25,MMO:0000163,in vivo visual assessment,,0.0,inferred from Kaplan-Meier plot analysis,,,,N-ethyl-N-nitrosourea (80 ug/g) ,98146,N-ethyl-N-nitrosourea (80 ug/g) ,,,,,,,, 2018,"van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28.",trigeminal nerve integrity trait,,RS:0004305,BDIX.BDIV-D6Rat132-D6Mgh3/Zte,female,200 days,47,,CMO:0002016,percentage of study population displaying trigeminal nerve neurilemmomas at a point in time,,SD approximated from 95%CI,,26,%,0.6929,4.75,MMO:0000163,in vivo visual assessment,,0.0,inferred from Kaplan-Meier plot analysis,,,,N-ethyl-N-nitrosourea (80 ug/g) ,98149,N-ethyl-N-nitrosourea (80 ug/g) ,,,,,,,, 2018,"van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28.",trigeminal nerve integrity trait,,RS:0004305,BDIX.BDIV-D6Rat132-D6Mgh3/Zte,both,200 days,86,,CMO:0002016,percentage of study population displaying trigeminal nerve neurilemmomas at a point in time,,SD approximated from 95%CI,,25,%,0.4583,4.25,MMO:0000163,in vivo visual assessment,,0.0,inferred from Kaplan-Meier plot analysis,,,,N-ethyl-N-nitrosourea (80 ug/g) ,98150,N-ethyl-N-nitrosourea (80 ug/g) ,,,,,,,, 2018,"van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28.",trigeminal nerve integrity trait,,RS:0004790,BDIX.BDIV-D6Rat132-D6Rat229/Zte,both,200 days,24,,CMO:0002016,percentage of study population displaying trigeminal nerve neurilemmomas at a point in time,,SD approximated from 95%CI,,19,%,1.7351,8.5,MMO:0000163,in vivo visual assessment,,0.0,inferred from Kaplan-Meier plot analysis,,,,N-ethyl-N-nitrosourea (80 ug/g) ,98151,N-ethyl-N-nitrosourea (80 ug/g) ,,,,,,,, 2018,"van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28.",trigeminal nerve integrity trait,,RS:0004306,BDIX.BDIV-D6Mit8-D6Rat229/Zte,male,200 days,56,,CMO:0002016,percentage of study population displaying trigeminal nerve neurilemmomas at a point in time,,SD approximated from 95%CI,,25,%,0.8018,6.0,MMO:0000163,in vivo visual assessment,,0.0,inferred from Kaplan-Meier plot analysis,,,,N-ethyl-N-nitrosourea (80 ug/g) ,98152,N-ethyl-N-nitrosourea (80 ug/g) ,,,,,,,, 2018,"van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28.",trigeminal nerve integrity trait,,RS:0004306,BDIX.BDIV-D6Mit8-D6Rat229/Zte,female,200 days,62,,CMO:0002016,percentage of study population displaying trigeminal nerve neurilemmomas at a point in time,,SD approximated from 95%CI,,26,%,0.7303,5.75,MMO:0000163,in vivo visual assessment,,0.0,inferred from Kaplan-Meier plot analysis,,,,N-ethyl-N-nitrosourea (80 ug/g) ,98153,N-ethyl-N-nitrosourea (80 ug/g) ,,,,,,,, 2018,"van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28.",trigeminal nerve integrity trait,,RS:0004306,BDIX.BDIV-D6Mit8-D6Rat229/Zte,both,200 days,118,,CMO:0002016,percentage of study population displaying trigeminal nerve neurilemmomas at a point in time,,SD approximated from 95%CI,,25,%,0.3682,4.0,MMO:0000163,in vivo visual assessment,,0.0,inferred from Kaplan-Meier plot analysis,,,,N-ethyl-N-nitrosourea (80 ug/g) ,98154,N-ethyl-N-nitrosourea (80 ug/g) ,,,,,,,, 2018,"van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28.",trigeminal nerve integrity trait,,RS:0000089,BDIV,male,200 days,63,,CMO:0002016,percentage of study population displaying trigeminal nerve neurilemmomas at a point in time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,inferred from Kaplan-Meier plot analysis,,,,N-ethyl-N-nitrosourea (80 ug/g) ,98155,N-ethyl-N-nitrosourea (80 ug/g) ,,,,,,,, 2018,"van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28.",trigeminal nerve integrity trait,,RS:0000089,BDIV,female,200 days,49,,CMO:0002016,percentage of study population displaying trigeminal nerve neurilemmomas at a point in time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,inferred from Kaplan-Meier plot analysis,,,,N-ethyl-N-nitrosourea (80 ug/g) ,98156,N-ethyl-N-nitrosourea (80 ug/g) ,,,,,,,, 2018,"van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28.",trigeminal nerve integrity trait,,RS:0000089,BDIV,both,200 days,112,,CMO:0002016,percentage of study population displaying trigeminal nerve neurilemmomas at a point in time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,inferred from Kaplan-Meier plot analysis,,,,N-ethyl-N-nitrosourea (80 ug/g) ,98157,N-ethyl-N-nitrosourea (80 ug/g) ,,,,,,,, 2018,"van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28.",life span trait,,RS:0000091,BDIX,male,200 days,57,,CMO:0003873,ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time,,ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time (CMO:0003873),,45,%,0.6623,5.0,MMO:0000163,in vivo visual assessment,,0.0,PI time in S1,ENU injection,200,days,N-ethyl-N-nitrosourea (80 mg/kg) ,98158,N-ethyl-N-nitrosourea (80 mg/kg) ,,,,,,,, 2018,"van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28.",life span trait,,RS:0000091,BDIX,female,200 days,52,,CMO:0003873,ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time,,ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time (CMO:0003873),,59,%,1.0747,7.75,MMO:0000163,in vivo visual assessment,,0.0,PI time in S1,ENU injection,200,days,N-ethyl-N-nitrosourea (80 mg/kg) ,98159,N-ethyl-N-nitrosourea (80 mg/kg) ,,,,,,,, 2018,"van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28.",life span trait,,RS:0000091,BDIX,both,200 days,109,,CMO:0003873,ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time,,ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time (CMO:0003873),,51,%,0.4789,5.0,MMO:0000163,in vivo visual assessment,,0.0,PI time in S1,ENU injection,200,days,N-ethyl-N-nitrosourea (80 mg/kg) ,98160,N-ethyl-N-nitrosourea (80 mg/kg) ,,,,,,,, 2018,"van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28.",life span trait,,RS:0004304,BDIX.BDIV-D6Mit1-D6Mgh2/Zte,male,200 days,51,,CMO:0003873,ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time,,ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time (CMO:0003873),,62,%,1.0502,7.5,MMO:0000163,in vivo visual assessment,,0.0,PI time in S1,ENU injection,200,days,N-ethyl-N-nitrosourea (80 mg/kg) ,98161,N-ethyl-N-nitrosourea (80 mg/kg) ,,,,,,,, 2018,"van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28.",life span trait,,RS:0004304,BDIX.BDIV-D6Mit1-D6Mgh2/Zte,female,200 days,49,,CMO:0003873,ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time,,ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time (CMO:0003873),,90,%,0.6429,4.5,MMO:0000163,in vivo visual assessment,,0.0,PI time in S1,ENU injection,200,days,N-ethyl-N-nitrosourea (80 mg/kg) ,98162,N-ethyl-N-nitrosourea (80 mg/kg) ,,,,,,,, 2018,"van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28.",life span trait,,RS:0004304,BDIX.BDIV-D6Mit1-D6Mgh2/Zte,both,200 days,100,,CMO:0003873,ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time,,ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time (CMO:0003873),,76,%,0.45,4.5,MMO:0000163,in vivo visual assessment,,0.0,PI time in S1,ENU injection,200,days,N-ethyl-N-nitrosourea (80 mg/kg) ,98163,N-ethyl-N-nitrosourea (80 mg/kg) ,,,,,,,, 2018,"van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28.",life span trait,,RS:0004305,BDIX.BDIV-D6Rat132-D6Mgh3/Zte,male,200 days,39,,CMO:0003873,ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time,,ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time (CMO:0003873),,78,%,1.1209,7.0,MMO:0000163,in vivo visual assessment,,0.0,PI time in S1,ENU injection,200,days,N-ethyl-N-nitrosourea (80 mg/kg) ,98164,N-ethyl-N-nitrosourea (80 mg/kg) ,,,,,,,, 2018,"van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28.",life span trait,,RS:0004305,BDIX.BDIV-D6Rat132-D6Mgh3/Zte,female,200 days,47,,CMO:0003873,ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time,,ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time (CMO:0003873),,74,%,0.6929,4.75,MMO:0000163,in vivo visual assessment,,0.0,PI time in S1,ENU injection,200,days,N-ethyl-N-nitrosourea (80 mg/kg) ,98165,N-ethyl-N-nitrosourea (80 mg/kg) ,,,,,,,, 2018,"van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28.",life span trait,,RS:0004305,BDIX.BDIV-D6Rat132-D6Mgh3/Zte,both,200 days,86,,CMO:0003873,ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time,,ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time (CMO:0003873),,75,%,0.4583,4.25,MMO:0000163,in vivo visual assessment,,0.0,PI time in S1,ENU injection,200,days,N-ethyl-N-nitrosourea (80 mg/kg) ,98166,N-ethyl-N-nitrosourea (80 mg/kg) ,,,,,,,, 2018,"van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28.",life span trait,,RS:0004790,BDIX.BDIV-D6Rat132-D6Rat229/Zte,both,200 days,24,,CMO:0003873,ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time,,ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time (CMO:0003873),,80,%,1.7861,8.75,MMO:0000163,in vivo visual assessment,,0.0,PI time in S1,ENU injection,200,days,N-ethyl-N-nitrosourea (80 mg/kg) ,98167,N-ethyl-N-nitrosourea (80 mg/kg) ,,,,,,,, 2018,"van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28.",life span trait,,RS:0004306,BDIX.BDIV-D6Mit8-D6Rat229/Zte,male,200 days,56,,CMO:0003873,ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time,,ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time (CMO:0003873),,75,%,0.8018,6.0,MMO:0000163,in vivo visual assessment,,0.0,PI time in S1,ENU injection,200,days,N-ethyl-N-nitrosourea (80 mg/kg) ,98168,N-ethyl-N-nitrosourea (80 mg/kg) ,,,,,,,, 2018,"van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28.",life span trait,,RS:0004306,BDIX.BDIV-D6Mit8-D6Rat229/Zte,female,200 days,62,,CMO:0003873,ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time,,ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time (CMO:0003873),,74,%,0.7303,5.75,MMO:0000163,in vivo visual assessment,,0.0,PI time in S1,ENU injection,200,days,N-ethyl-N-nitrosourea (80 mg/kg) ,98169,N-ethyl-N-nitrosourea (80 mg/kg) ,,,,,,,, 2018,"van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28.",life span trait,,RS:0004306,BDIX.BDIV-D6Mit8-D6Rat229/Zte,both,200 days,118,,CMO:0003873,ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time,,ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time (CMO:0003873),,75,%,0.3682,4.0,MMO:0000163,in vivo visual assessment,,0.0,PI time in S1,ENU injection,200,days,N-ethyl-N-nitrosourea (80 mg/kg) ,98170,N-ethyl-N-nitrosourea (80 mg/kg) ,,,,,,,, 2018,"van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28.",life span trait,,RS:0000089,BDIV,male,200 days,63,,CMO:0003873,ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time,,ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time (CMO:0003873),,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,PI time in S1,ENU injection,200,days,N-ethyl-N-nitrosourea (80 mg/kg) ,98171,N-ethyl-N-nitrosourea (80 mg/kg) ,,,,,,,, 2018,"van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28.",life span trait,,RS:0000089,BDIV,female,200 days,49,,CMO:0003873,ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time,,ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time (CMO:0003873),,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,PI time in S1,ENU injection,200,days,N-ethyl-N-nitrosourea (80 mg/kg) ,98172,N-ethyl-N-nitrosourea (80 mg/kg) ,,,,,,,, 2018,"van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28.",life span trait,,RS:0000089,BDIV,both,200 days,112,,CMO:0003873,ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time,,ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time (CMO:0003873),,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,PI time in S1,ENU injection,200,days,N-ethyl-N-nitrosourea (80 mg/kg) ,98173,N-ethyl-N-nitrosourea (80 mg/kg) ,,,,,,,, 2018,"van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28.",trigeminal nerve integrity trait,,RS:0000091,BDIX,male,200 days,57,,CMO:0002016,percentage of study population displaying trigeminal nerve neurilemmomas at a point in time,,SD approximated from 95%CI,,55,%,0.8941,6.75,MMO:0000163,in vivo visual assessment,,0.0,inferred from Kaplan-Meier plot analysis,,,,N-ethyl-N-nitrosourea (80 ug/g) ,98142,N-ethyl-N-nitrosourea (80 ug/g) ,,,,,,,, 2018,"van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28.",trigeminal nerve integrity trait,,RS:0004304,BDIX.BDIV-D6Mit1-D6Mgh2/Zte,both,200 days,100,,CMO:0002016,percentage of study population displaying trigeminal nerve neurilemmomas at a point in time,,SD approximated from 95%CI,,24,%,0.45,4.5,MMO:0000163,in vivo visual assessment,,0.0,inferred from Kaplan-Meier plot analysis,,,,N-ethyl-N-nitrosourea (80 ug/g) ,98147,N-ethyl-N-nitrosourea (80 ug/g) ,,,,,,,, 3186,"Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20.",central nervous system integrity trait,,RS:0000566,LOU/M,not specified,114 days to 95 days,4,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,100,%,0.0,0.0,MMO:0000163,in vivo visual assessment,,2592000.0,,,,,Freund's complete adjuvant (0.05-0.1 ml) and human myelin basic protein (0.05-0.1 ml) and cyclophosphamide (5 mg) then cyclophosphamide (8 mg) ,110793,Freund's complete adjuvant (0.05-0.1 ml) ,human myelin basic protein (0.05-0.1 ml) ,cyclophosphamide (5 mg) ,cyclophosphamide (8 mg) ,,,,, 3186,"Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20.",central nervous system integrity trait,,RS:0000566,LOU/M,not specified,114 days to 95 days,3,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,100,%,0.0,0.0,MMO:0000163,in vivo visual assessment,,2592000.0,,,,,Freund's complete adjuvant (0.05-0.1 ml) and Hu-S102-129 (0.05-0.1 ml) then pertussis toxin (3.5 ug) then pertussis toxin (3.5 ug) ,110794,Freund's complete adjuvant (0.05-0.1 ml) ,Hu-S102-129 (0.05-0.1 ml) ,,pertussis toxin (3.5 ug) ,,,pertussis toxin (3.5 ug) ,, 3186,"Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20.",central nervous system integrity trait,,RS:0000566,LOU/M,not specified,114 days to 95 days,4,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,100,%,0.0,0.0,MMO:0000163,in vivo visual assessment,,2592000.0,,,,,Freund's complete adjuvant (0.05-0.1 ml) and Hu-S110-129 (0.05-0.1 ml) then pertussis toxin (3.5 ug) then pertussis toxin (3.5 ug) ,110795,Freund's complete adjuvant (0.05-0.1 ml) ,Hu-S110-129 (0.05-0.1 ml) ,,pertussis toxin (3.5 ug) ,,,pertussis toxin (3.5 ug) ,, 3186,"Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20.",central nervous system integrity trait,,RS:0000566,LOU/M,not specified,114 days to 95 days,5,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,11,d,0.0,0.0,MMO:0000163,in vivo visual assessment,,2592000.0,,,,,Freund's complete adjuvant (0.05-0.1 ml) and human myelin basic protein (0.05-0.1 ml) then pertussis toxin (3.5 ug) then pertussis toxin (3.5 ug) ,110796,Freund's complete adjuvant (0.05-0.1 ml) ,human myelin basic protein (0.05-0.1 ml) ,,pertussis toxin (3.5 ug) ,,,pertussis toxin (3.5 ug) ,, 3186,"Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20.",central nervous system integrity trait,,RS:0000566,LOU/M,not specified,114 days to 95 days,4,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,11,d,0.0,0.0,MMO:0000163,in vivo visual assessment,,2592000.0,,,,,Freund's complete adjuvant (0.05-0.1 ml) and human myelin basic protein (0.05-0.1 ml) and cyclophosphamide (8 mg) then cyclophosphamide (5 mg) ,110797,Freund's complete adjuvant (0.05-0.1 ml) ,human myelin basic protein (0.05-0.1 ml) ,cyclophosphamide (8 mg) ,cyclophosphamide (5 mg) ,,,,, 3186,"Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20.",central nervous system integrity trait,,RS:0000566,LOU/M,not specified,114 days to 95 days,3,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,11,d,0.0,0.0,MMO:0000163,in vivo visual assessment,,2592000.0,,,,,Freund's complete adjuvant (0.05-0.1 ml) and Hu-S102-129 (0.05-0.1 ml) then pertussis toxin (3.5 ug) then pertussis toxin (3.5 ug) ,110798,Freund's complete adjuvant (0.05-0.1 ml) ,Hu-S102-129 (0.05-0.1 ml) ,,pertussis toxin (3.5 ug) ,,,pertussis toxin (3.5 ug) ,, 3186,"Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20.",central nervous system integrity trait,,RS:0000566,LOU/M,not specified,114 days to 95 days,4,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,11,d,0.0,0.0,MMO:0000163,in vivo visual assessment,,2592000.0,,,,,Freund's complete adjuvant (0.05-0.1 ml) and Hu-S110-129 (0.05-0.1 ml) then pertussis toxin (3.5 ug) then pertussis toxin (3.5 ug) ,110799,Freund's complete adjuvant (0.05-0.1 ml) ,Hu-S110-129 (0.05-0.1 ml) ,,pertussis toxin (3.5 ug) ,,,pertussis toxin (3.5 ug) ,, 3186,"Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20.",central nervous system integrity trait,,RS:0000566,LOU/M,not specified,114 days to 95 days,5,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,,,8,d,0.0,0.0,MMO:0000163,in vivo visual assessment,,2592000.0,,,,,Freund's complete adjuvant (0.05-0.1 ml) and human myelin basic protein (0.05-0.1 ml) then pertussis toxin (3.5 ug) then pertussis toxin (3.5 ug) ,110800,Freund's complete adjuvant (0.05-0.1 ml) ,human myelin basic protein (0.05-0.1 ml) ,,pertussis toxin (3.5 ug) ,,,pertussis toxin (3.5 ug) ,, 3186,"Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20.",central nervous system integrity trait,,RS:0000566,LOU/M,not specified,114 days to 95 days,4,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,,,11,d,0.0,0.0,MMO:0000163,in vivo visual assessment,,2592000.0,,,,,Freund's complete adjuvant (0.05-0.1 ml) and human myelin basic protein (0.05-0.1 ml) and cyclophosphamide (8 mg) then cyclophosphamide (5 mg) ,110801,Freund's complete adjuvant (0.05-0.1 ml) ,human myelin basic protein (0.05-0.1 ml) ,cyclophosphamide (8 mg) ,cyclophosphamide (5 mg) ,,,,, 3186,"Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20.",central nervous system integrity trait,,RS:0000566,LOU/M,not specified,114 days to 95 days,4,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,,,8,d,0.0,0.0,MMO:0000163,in vivo visual assessment,,2592000.0,,,,,Freund's complete adjuvant (0.05-0.1 ml) and Hu-S110-129 (0.05-0.1 ml) then pertussis toxin (3.5 ug) then pertussis toxin (3.5 ug) ,110803,Freund's complete adjuvant (0.05-0.1 ml) ,Hu-S110-129 (0.05-0.1 ml) ,,pertussis toxin (3.5 ug) ,,,pertussis toxin (3.5 ug) ,, 3186,"Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20.",central nervous system integrity trait,,RS:0000566,LOU/M,not specified,114 days to 95 days,3,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,5,d,0.0,0.0,MMO:0000163,in vivo visual assessment,,0.0,,,,,rat anti-Hu-S102-129 T cell line (9 x 10E6 cells) ,110782,rat anti-Hu-S102-129 T cell line (9 x 10E6 cells) ,,,,,,,, 3186,"Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20.",central nervous system integrity trait,,RS:0000566,LOU/M,not specified,114 days to 95 days,9,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,rat anti-Hu-MBP T cell line (9 x 10E6 cells) ,110780,rat anti-Hu-MBP T cell line (9 x 10E6 cells) ,,,,,,,, 3186,"Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20.",central nervous system integrity trait,,RS:0000566,LOU/M,not specified,114 days to 95 days,3,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,,,8,d,0.0,0.0,MMO:0000163,in vivo visual assessment,,0.0,,,,,rat anti-Hu-S102-129 T cell line (9 x 10E6 cells) ,110789,rat anti-Hu-S102-129 T cell line (9 x 10E6 cells) ,,,,,,,, 3186,"Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20.",central nervous system integrity trait,,RS:0000566,LOU/M,not specified,114 days to 95 days,4,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,0,%,0.0,0.0,MMO:0000163,in vivo visual assessment,,2592000.0,,,,,Freund's complete adjuvant (0.05-0.1 ml) and human myelin basic protein (0.05-0.1 ml) ,110790,Freund's complete adjuvant (0.05-0.1 ml) ,human myelin basic protein (0.05-0.1 ml) ,,,,,,, 3186,"Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20.",central nervous system integrity trait,,RS:0000566,LOU/M,not specified,114 days to 95 days,4,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,0,%,0.0,0.0,MMO:0000163,in vivo visual assessment,,2592000.0,,,,,Freund's complete adjuvant (0.05-0.1 ml) and Hu-S110-129 (0.05-0.1 ml) ,110791,Freund's complete adjuvant (0.05-0.1 ml) ,Hu-S110-129 (0.05-0.1 ml) ,,,,,,, 3186,"Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20.",central nervous system integrity trait,,RS:0000566,LOU/M,not specified,114 days to 95 days,5,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,100,%,0.0,0.0,MMO:0000163,in vivo visual assessment,,2592000.0,,,,,Freund's complete adjuvant (0.05-0.1 ml) and human myelin basic protein (0.05-0.1 ml) then pertussis toxin (3.5 ug) then pertussis toxin (3.5 ug) ,110792,Freund's complete adjuvant (0.05-0.1 ml) ,human myelin basic protein (0.05-0.1 ml) ,,pertussis toxin (3.5 ug) ,,,pertussis toxin (3.5 ug) ,, 3186,"Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20.",central nervous system integrity trait,,RS:0000566,LOU/M,not specified,114 days to 95 days,3,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,,,8,d,0.0,0.0,MMO:0000163,in vivo visual assessment,,2592000.0,,,,,Freund's complete adjuvant (0.05-0.1 ml) and Hu-S102-129 (0.05-0.1 ml) then pertussis toxin (3.5 ug) then pertussis toxin (3.5 ug) ,110802,Freund's complete adjuvant (0.05-0.1 ml) ,Hu-S102-129 (0.05-0.1 ml) ,,pertussis toxin (3.5 ug) ,,,pertussis toxin (3.5 ug) ,, 3186,"Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20.",central nervous system integrity trait,,RS:0000566,LOU/M,not specified,114 days to 95 days,3,,CMO:0001047,percentage of study population developing experimental autoimmune encephalomyelitis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,rat anti-Hu-S102-129 T cell line (9 x 10E6 cells) ,110781,rat anti-Hu-S102-129 T cell line (9 x 10E6 cells) ,,,,,,,, 3186,"Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20.",central nervous system integrity trait,,RS:0000566,LOU/M,not specified,114 days to 95 days,9,,CMO:0001422,post-insult time to onset of experimental autoimmune encephalomyelitis,,,,6,d,1.0,3.0,MMO:0000163,in vivo visual assessment,,0.0,,,,,rat anti-Hu-MBP T cell line (9 x 10E6 cells) ,110783,rat anti-Hu-MBP T cell line (9 x 10E6 cells) ,,,,,,,, 3186,"Hashim G, etal., J Immunol. 1991 Jan 15;146(2):515-20.",central nervous system integrity trait,,RS:0000566,LOU/M,not specified,114 days to 95 days,9,,CMO:0001424,experimental autoimmune encephalomyelitis duration,,,,6,d,1.0,3.0,MMO:0000163,in vivo visual assessment,,0.0,,,,,rat anti-Hu-MBP T cell line (9 x 10E6 cells) ,110784,rat anti-Hu-MBP T cell line (9 x 10E6 cells) ,,,,,,,, 3182,"Ragaeva DS, et al., Physiol Behav. 2017 Jun 1;175:22-30. doi: 10.1016/j.physbeh.2017.03.026. Epub 2017 Mar 21.",single birth offspring quantity,,RS:0001334,ISIAH,female,112 days to 98 days,5,,CMO:0000642,litter size,,,,8.6,,2.1,4.6957,MMO:0000163,in vivo visual assessment,,0.0,,,,,control condition,110669,control condition,,,,,,,, 3182,"Ragaeva DS, et al., Physiol Behav. 2017 Jun 1;175:22-30. doi: 10.1016/j.physbeh.2017.03.026. Epub 2017 Mar 21.",single birth offspring quantity,,RS:0003766,WAG/Nov,female,112 days to 98 days,5,,CMO:0000642,litter size,,,,7.6,,0.7,1.5652,MMO:0000163,in vivo visual assessment,,0.0,,,,,control condition,110670,control condition,,,,,,,, 3196,"Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562.",life span trait,,RS:0001792,BDIX/OrlCrl,male,163 days to 77 days,16,,CMO:0002737,ratio of survivors to total study population during a period of time,,saline control group,,19,%,0.0,0.0,MMO:0000163,in vivo visual assessment,,0.0,two treatment regimen,,100,days,DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 0.9% sodium chloride solution (2 ml) (for 7 days) then 0.9% sodium chloride solution (2 ml) (for 7 days),111146,DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours),splenectomy,,0.9% sodium chloride solution (2 ml) (for 7 days),,,0.9% sodium chloride solution (2 ml) (for 7 days),, 3196,"Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562.",life span trait,,RS:0001792,BDIX/OrlCrl,male,163 days to 77 days,18,,CMO:0002737,ratio of survivors to total study population during a period of time,,fluorouracil 5-FU,,39,%,,,MMO:0000163,in vivo visual assessment,,0.0,two treatment,,100,days,DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) then 5-fluorouracil (100 mg/kg) (for 7 days),111147,DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours),splenectomy,,5-fluorouracil (100 mg/kg) (for 7 days),,,5-fluorouracil (100 mg/kg) (for 7 days),, 3196,"Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562.",life span trait,,RS:0001792,BDIX/OrlCrl,male,163 days to 77 days,18,,CMO:0002737,ratio of survivors to total study population during a period of time,,5-fluorouracil + interleukin-2,,44,%,,,MMO:0000163,in vivo visual assessment,,0.0,two treatments,,100,days,DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days),111148,DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours),splenectomy,,5-fluorouracil (100 mg/kg) (for 7 days),interleukin-2 (75000 U/d) (for 4 days),,5-fluorouracil (100 mg/kg) (for 7 days),interleukin-2 (75000 U/d) (for 4 days), 3196,"Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562.",life span trait,,RS:0001792,BDIX/OrlCrl,male,163 days to 77 days,21,,CMO:0002737,ratio of survivors to total study population during a period of time,,5-fluorouracil + thymosin alpha-1 +interleukin-2,,81,%,,,MMO:0000163,in vivo visual assessment,,0.0,two treatments,,100,days,DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and Thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and Thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days),111149,DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours),splenectomy,,5-fluorouracil (100 mg/kg) (for 7 days),Thymosin alpha-1 (200 ug/kg) (for 4 days),interleukin-2 (75000 U/d) (for 4 days),5-fluorouracil (100 mg/kg) (for 7 days),Thymosin alpha-1 (200 ug/kg) (for 4 days),interleukin-2 (75000 U/d) (for 4 days) 3196,"Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562.",life span trait,,RS:0001792,BDIX/OrlCrl,male,213 days to 77 days,16,,CMO:0002737,ratio of survivors to total study population during a period of time,,saline control group,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,two treatment regimen,,150,days,DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 0.9% sodium chloride solution (2 ml) (for 7 days) then 0.9% sodium chloride solution (2 ml) (for 7 days),111150,DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours),splenectomy,,0.9% sodium chloride solution (2 ml) (for 7 days),,,0.9% sodium chloride solution (2 ml) (for 7 days),, 3196,"Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562.",life span trait,,RS:0001792,BDIX/OrlCrl,male,213 days to 77 days,18,,CMO:0002737,ratio of survivors to total study population during a period of time,,fluorouracil 5-FU,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,two treatment,,150,days,DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) then 5-fluorouracil (100 mg/kg) (for 7 days),111151,DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours),splenectomy,,5-fluorouracil (100 mg/kg) (for 7 days),,,5-fluorouracil (100 mg/kg) (for 7 days),, 3196,"Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562.",life span trait,,RS:0001792,BDIX/OrlCrl,male,213 days to 77 days,18,,CMO:0002737,ratio of survivors to total study population during a period of time,,5-fluorouracil + interleukin-2,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,two treatments,,150,days,DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days),111152,DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours),splenectomy,,5-fluorouracil (100 mg/kg) (for 7 days),interleukin-2 (75000 U/d) (for 4 days),,5-fluorouracil (100 mg/kg) (for 7 days),interleukin-2 (75000 U/d) (for 4 days), 3196,"Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562.",life span trait,,RS:0001792,BDIX/OrlCrl,male,213 days to 77 days,21,,CMO:0002737,ratio of survivors to total study population during a period of time,,5-fluorouracil + thymosin alpha-1 +interleukin-2,,9.5,%,,,MMO:0000163,in vivo visual assessment,,0.0,two treatments,,150,days,DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and Thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and Thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days),111153,DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours),splenectomy,,5-fluorouracil (100 mg/kg) (for 7 days),Thymosin alpha-1 (200 ug/kg) (for 4 days),interleukin-2 (75000 U/d) (for 4 days),5-fluorouracil (100 mg/kg) (for 7 days),Thymosin alpha-1 (200 ug/kg) (for 4 days),interleukin-2 (75000 U/d) (for 4 days) 3184,"McCarron A, et al., Am J Pathol. 2020 May;190(5):977-993. doi: 10.1016/j.ajpath.2020.01.009. Epub 2020 Feb 18.",total life span,,RS:0005134,SD-Cftrem1Apb,not specified,7 days,N/A,,CMO:0003879,ratio of survivors of meconium ileus to total study population during a period of time,,ratio of survivors of meconium ileus to total study population during a period of time (CMO:0003879),,84,%,0.0,,MMO:0000163,in vivo visual assessment,,0.0,,,,,control condition,111459,control condition,,,,,,,, 3184,"McCarron A, et al., Am J Pathol. 2020 May;190(5):977-993. doi: 10.1016/j.ajpath.2020.01.009. Epub 2020 Feb 18.",fertility trait,,RS:0005133,Sah:SD,female,0 days,N/A,,CMO:0000642,litter size,,Sah:SD (RS:0005133),,10.2,,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,control condition,111383,control condition,,,,,,,, 3184,"McCarron A, et al., Am J Pathol. 2020 May;190(5):977-993. doi: 10.1016/j.ajpath.2020.01.009. Epub 2020 Feb 18.",fertility trait,,RS:0005134,SD-Cftrem1Apb,female,0 days,3,,CMO:0000642,litter size,,3 het p508 x 3 homo p508 16 litters,,9.8,,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,control condition,110764,control condition,,,,,,,, 3184,"McCarron A, et al., Am J Pathol. 2020 May;190(5):977-993. doi: 10.1016/j.ajpath.2020.01.009. Epub 2020 Feb 18.",fertility trait,,RS:0005135,SD-Cftrem2Apb,female,0 days,N/A,,CMO:0000642,litter size,,"SD-Cftrem2Apb (RS:0005135), 7 het ko trios 26 litters",,11.7,,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,control condition,110765,control condition,,,,,,,, 3184,"McCarron A, et al., Am J Pathol. 2020 May;190(5):977-993. doi: 10.1016/j.ajpath.2020.01.009. Epub 2020 Feb 18.",total life span,,RS:0005135,SD-Cftrem2Apb,not specified,7 days,N/A,,CMO:0003879,ratio of survivors of meconium ileus to total study population during a period of time,,ratio of survivors of meconium ileus to total study population during a period of time (CMO:0003879),,60,%,0.0,,MMO:0000163,in vivo visual assessment,,0.0,,,,,controlled ColonLYTELY content drinking water (4.5 %) (for 7 days),111460,controlled ColonLYTELY content drinking water (4.5 %) (for 7 days),,,,,,,, 3184,"McCarron A, et al., Am J Pathol. 2020 May;190(5):977-993. doi: 10.1016/j.ajpath.2020.01.009. Epub 2020 Feb 18.",total life span,,RS:0005135,SD-Cftrem2Apb,not specified,60 days,N/A,,CMO:0003879,ratio of survivors of meconium ileus to total study population during a period of time,,ratio of survivors of meconium ileus to total study population during a period of time (CMO:0003879),,34,%,0.0,,MMO:0000163,in vivo visual assessment,,0.0,,,,,controlled ColonLYTELY content drinking water (4.5 %) (for 60 days),111462,controlled ColonLYTELY content drinking water (4.5 %) (for 60 days),,,,,,,, 3184,"McCarron A, et al., Am J Pathol. 2020 May;190(5):977-993. doi: 10.1016/j.ajpath.2020.01.009. Epub 2020 Feb 18.",total life span,,RS:0005134,SD-Cftrem1Apb,not specified,60 days,N/A,,CMO:0003879,ratio of survivors of meconium ileus to total study population during a period of time,,ratio of survivors of meconium ileus to total study population during a period of time (CMO:0003879),,66,%,0.0,,MMO:0000163,in vivo visual assessment,,0.0,,,,,control condition,111461,control condition,,,,,,,,